1. Introduction {#sec1-molecules-24-04318}
===============

Biotherapeutics such as protein-based therapeutics are a fast-growing group of pharmaceuticals \[[@B1-molecules-24-04318]\]. Although the advantage of biotherapeutics is their target specificity, one of the major challenges in the way of further development of protein-based therapeutics is their intracellular delivery. A huge hydrophilic proteinaceous macromolecule cannot cross the hydrophobic lipid bilayer membrane surrounding a cell \[[@B2-molecules-24-04318]\]. This obstacle, however, can be overcome with the assistance of a cell-penetrating peptide (CPP).

CPPs are short relatively non-toxic peptide sequences, usually less than 30 amino acids, which not only have the ability to cross cellular membranes, but also can co-transport a variety of biologically active molecules (cargoes) inside the cells \[[@B1-molecules-24-04318],[@B2-molecules-24-04318]\]. Since their discovery in 1988, a wide range of different CPPs has been identified and subjected to clinical trial studies \[[@B3-molecules-24-04318],[@B4-molecules-24-04318]\]. Chemically, CPPs are categorized into three classes, known as cationic, hydrophobic, and amphipathic. Cationic CPPs have positively charged residues that are capable of interacting with negatively charged groups on the cellular membrane, which results in their internalization \[[@B5-molecules-24-04318]\]. Hydrophobic CPPs have mainly nonpolar residues that can interact with the hydrophobic segments of the membrane \[[@B6-molecules-24-04318]\]. Despite the presence of both polar and non-polar residues in amphipathic CPPs, some non-amphipathic peptides can display amphipathic behavior after folding into α-helices or β-sheets \[[@B7-molecules-24-04318]\].

Considering CPPs as appropriate delivery vectors for proteinaceous therapeutics \[[@B8-molecules-24-04318]\], two main strategies are available to enable CPPs for the co-transportation of the desired cargo molecules across the plasma membrane. These systems might be designed in the form of covalent conjugation of the CPP and the cargo molecule or as a non-covalent complex of CPP and cargo \[[@B9-molecules-24-04318]\]. Covalent conjugation can be established using chemical synthesis methods \[[@B10-molecules-24-04318],[@B11-molecules-24-04318],[@B12-molecules-24-04318]\]. However, for protein or peptide cargos, covalent conjugation to CPPs can be accomplished by expressing the chimeric gene in bacterial expression systems such as *E. coli* \[[@B13-molecules-24-04318],[@B14-molecules-24-04318]\].

There are some other limitations and challenges regarding protein-based therapeutics, such as low solubility, short half-life, and the induction of unwanted or fatal allergic and immunological responses in the recipients. For engineered CPP-protein conjugates, wherein new amino acid orders are added to the target protein, some further issues in addition to the above-mentioned challenges must be addressed, including incorrect folding of the engineered protein, changes in 3D structures and backbones, and variations in the side chains that stabilize the structure \[[@B15-molecules-24-04318],[@B16-molecules-24-04318]\].

Although more than one thousand experimentally validated CPPs have been identified \[[@B17-molecules-24-04318]\], a universal method to discriminate between CPPs and designate the ideal peptide for a conjugation is not currently available. Arbitrarily selecting a frequently used CPP might not necessarily result in the design of an optimal bio-conjugate \[[@B18-molecules-24-04318]\]. Therefore, in the covalent conjugation of CPPs to a protein, there are several issues that still need to be addressed in the process of CPP selection, including: (1) consideration of CPPs that provide a higher penetration of the conjugate; (2) evaluating the degree of CPP interference with the stereochemistry of the conjugate; (3) pondering CPPs with higher solubility and stability in the production and formulation process; (4) assessing CPPs that do not result in the aggregation of the cargo after delivery; and (5) inspecting the degree of potential allergenicity, protease sensitivity, and hemolysis of the conjugate. Hence, devising a realistic workflow to follow the aforementioned criteria in the selection process of the appropriate CPP is one of the most influential factors affecting the structural and functional properties of the target protein.

Using a guideline considering computational approaches in the rational design of a chimera would provide the opportunity to envisage part of the abovementioned criteria and attain a comprehensible understanding of the protein's characteristics \[[@B19-molecules-24-04318],[@B20-molecules-24-04318]\]. Herein, the credit goes to the improvement in the software or web-based portals with strong algorithms that determine the structure of the conjugates and predict the in vivo effects of the chimera.

Therefore, we propose a bioinformatics guideline using some already existing in silico methods to select the best CPP candidates in conjugation with carboxypeptidase G2 (CPG2) enzyme as the model cargo molecule. CPG2 also known as glucarpidase (Voraxaz^®^) is an FDA-approved bacterial enzyme breaking methotrexate (MTX) down into two noncytotoxic metabolites \[[@B21-molecules-24-04318],[@B22-molecules-24-04318],[@B23-molecules-24-04318]\]. Due to its capacity for hydrolyzing a wide range of folate analogs, CPG2 is also able to convert non-toxic glutamated nitrogen mustard prodrugs into cytotoxic substances; hence, it is proposed as an intriguing choice for the antibody/gene-directed enzyme prodrug therapy modalities known as ADEPT and GDEPT, respectively \[[@B24-molecules-24-04318],[@B25-molecules-24-04318],[@B26-molecules-24-04318]\]. In glucarpidase therapy, the enzyme only reduces the circulating MTX levels and has no access to the drug inside the cells. Therefore, there is a rebound of MTX into the blood due to the release of intracellular stored MTX \[[@B27-molecules-24-04318]\]. Accordingly, it seems reasonable to deliver the CPG2 enzyme to the intracellular compartment. Through experimental studies, we have recently achieved the intracellular delivery of CPG2 in conjugation with the well-known transcription transactivator protein of HIV-1 (TAT) peptide \[[@B28-molecules-24-04318]\]. Therefore, CPG2 has been used as the model cargo in the preparation of the current investigation.

Within this study, we describe significant factors affecting CPP-CPG2 recombinant conjugate and will introduce a guideline for the design of CPP-protein conjugates. This instruction would provide a workflow using available bioinformatics tools to design an effective biotherapeutic with the optimum pharmacological responses and the fewest side effects. It is expected that this guideline will be useful for scientists of different disciplines regarding protein engineering and delivery.

2. Results and Discussions {#sec2-molecules-24-04318}
==========================

2.1. Primary Dataset and Penetration Prediction of CPPs {#sec2dot1-molecules-24-04318}
-------------------------------------------------------

Unique linear CPPs with natural L-conformation amino acids were retrieved from CPPsite 2.0. In general, CPPs with the highest uptake efficiency are preferred for conjugation. Hence, CPP sequences were submitted to the CPPred-RF server to determine the degree of cellular uptake ([Table S1](#app1-molecules-24-04318){ref-type="app"}). The CPPred-RF webserver is a two-layered prediction engine. The first layer is based on some features, such as physicochemical properties and dipeptide composition. This layer defines if the submitted sequence is cell-penetrating. When the peptide is cell-penetrating, then the second layer of prediction estimates the uptake of the peptide by cells as high or low. In each layer, prediction confidence is reported. Finally, 70 peptides that were predicted to have the highest uptake efficiency with the prediction confidence of above 0.9 were subjected to further analyses ([Table 1](#molecules-24-04318-t001){ref-type="table"}). We have checked whether the 70 top selected CPPs have shown adequate uptake efficiency in experimental studies. The data on previously studied top CPPs, as well as the category of each CPP, are available in [Table 2](#molecules-24-04318-t002){ref-type="table"}. Levels of uptake for 66 out of 70 CPPs were available from laboratory experiments. As presented in [Table 2](#molecules-24-04318-t002){ref-type="table"}, all of the 70 selected CPPs have displayed either high or medium uptake efficiency.

There is some evidence available that the secondary structure of an amphipathic CPP is correlated to its uptake efficiency \[[@B46-molecules-24-04318],[@B47-molecules-24-04318],[@B48-molecules-24-04318]\]. Therefore, secondary structures of the top 70 CPPs after conjugation with CPG2, for both N- and C-terminal positions were recorded. When a CPP folds into an α-helix or β-sheet it potentially penetrates the cells more efficiently. Therefore, the percentage of amino acids that are able to form helices and sheets was calculated for the CPP fragment within each conjugate ([Table 3](#molecules-24-04318-t003){ref-type="table"}). According to the acquired results, peptides 3, 4, 6, 14, 56, and 62 in N-terminal and peptides 2, 14, 43, 52, 56, and 58 in C-terminal conjugation have more than 85% amino acids with helix and sheet configuration. It should be noted that compared with the C-terminal conjugation of CPPs, N-terminal homologs resulted in a significantly higher percentage of amino acids with the helix and sheet configuration ([Figure 1](#molecules-24-04318-f001){ref-type="fig"}).

2.2. mRNA Secondary Structure Prediction of cpp-cpg2/cpg2-cpp Conjugates {#sec2dot2-molecules-24-04318}
------------------------------------------------------------------------

The stability of the mRNA structure affects the expression level of proteins. A more positive *ΔG* value of the mRNA secondary structure in the translation initiation region correlates with a higher probability of the translation of mRNA into protein \[[@B49-molecules-24-04318]\]. The obtained *ΔG* values from the mfold server indicated that 74% of the N-terminal conjugates had higher *ΔG* values compared with the unconjugated CPG2. N-terminal conjugates from peptides 10, 18, 31, 36, and 61 displayed the highest *ΔG* values. Besides *ΔG*, the level of exposure of the AUG start codon in the mRNA secondary structure has a regulatory effect on the rate of protein translation in *E. coli*. If the start codon locates on a loop, higher exposure to the ribosomal subunit occurs and results in a higher level of translation compared with a start codon on the stem \[[@B50-molecules-24-04318]\]. In this study, in 50% of the N-terminal conjugates, the start codon was located on a loop and in the rest of the conjugates, as well as CPG2 itself, the starting codon was on the stem. Secondary structures of two conjugates and CPG2 are shown in [Figure 2](#molecules-24-04318-f002){ref-type="fig"}. The *N*-terminal conjugate of "R9-CPG2" has a high *ΔG* value (−1.6 kcal.mol^−1^) and an exposed start codon, while "Transportan 10-CPG2" *N*-terminal conjugate displays a low *ΔG* value (−13.2 kcal.mol^−1^) and its start codon is not exposed. *ΔG* values and position of the start codon for all of the conjugates are available in [Table S2](#app1-molecules-24-04318){ref-type="app"}. It should be noted that all the seventy C-terminal conjugates have the same initiation translation region as the control unconjugated CPG2.

2.3. Physiochemical Properties of CPPs and CPP-CPG2/CPG2-CPP Conjugates {#sec2dot3-molecules-24-04318}
-----------------------------------------------------------------------

Various physiochemical properties were calculated for CPG2 and the top 70 CPPs both alone ([Table S3](#app1-molecules-24-04318){ref-type="app"}) and in conjugation to CPG2 at the *N*-terminal ([Table 4](#molecules-24-04318-t004){ref-type="table"}) and C-terminal ([Table S4](#app1-molecules-24-04318){ref-type="app"}) positions via ProtParam tool. Top 70 CPPs' lengths were between 5-22 amino acids. All the top 70 CPPs except number 69 have basic pI ([Table S3](#app1-molecules-24-04318){ref-type="app"}), indicating an overall positive charge in the blood pH (7.4). The pI of unconjugated CPG2 was calculated to be 6.22. Only fusion proteins resulting from peptides 12, 66, 67, 68, and 69 had an acidic pI due to the anionic nature of CPPs ([Table 4](#molecules-24-04318-t004){ref-type="table"}). The rest of the conjugates would have an overall positive charge at pH = 7.4. None of the conjugates had a pI near 7.4, indicating a low risk of protein aggregation due to pI after administration.

The instability index for all the conjugates is less than 40, indicating that the conjugates are probably stable in the test tube. However, only conjugates resulting from peptides 1, 3, 12, 14, 55, and 67 do not have elevated instability index compared with the unconjugated CPG2. GRAVY value for all the conjugates is negative, which means all of them are hydrophilic. Compared with CPG2, the GRAVY for conjugates resulting from peptides 1, 12, 14, 28, 29, 30, 32, 33, 66, 67, 68, and 69 showed higher values which could result in higher hydrophobicity. This might, in turn, leads to an increased chance of aggregation. All the conjugates composed of "CPP5s" and "pVEC mutants" showed an increase in GRAVY value compared with CPG2. There was no significant difference between the physiochemical properties of the N- and C-terminal conjugates.

2.4. The Solubility of CPP-CPG2 and CPG2-CPP Conjugates {#sec2dot4-molecules-24-04318}
-------------------------------------------------------

The solubility of the top 70 CPPs conjugated to CPG2, regarding both N- and C-terminal conjugations were predicted using the ccSOL server ([Table 5](#molecules-24-04318-t005){ref-type="table"}). The solubility of proteins is a crucial factor for the production, formulation, and delivery of protein-based therapeutics. Solubility is influenced by extrinsic and intrinsic factors. By optimizing extrinsic factors such as pH, ionic strength, the temperature of the solvent, and in the presence of various additives, protein solubility can be increased. The intrinsic factors are mostly related to the amino acids on the proteins' surface \[[@B51-molecules-24-04318]\]. CPPs have been used to increase the aqueous solubility of their cargo. For instance, the conjugation of taxol to CPPs resulted in the improvement of taxol's poor solubility \[[@B52-molecules-24-04318],[@B53-molecules-24-04318]\]. CcSol predicts the percentage of protein solubility. On average, conjugates from "CCP5s" and some "Crot derivatives" displayed an overall higher solubility score. Higher solubility of the "CCP5" family might be due to the increased negative charge on the protein's surface associated with the anionic nature of these CPPs \[[@B51-molecules-24-04318]\]. However, due to differences between results from different solubility prediction servers, further experimental validations are required to reach a definite conclusion. The *N*- and C-terminal CPP-CPG2 and CPG2-CPP conjugates had an average solubility of 79.69% and 79.44%, respectively. Therefore, the position of a conjugation had no significant effect on the solubility.

2.5. Three-Dimensional Modeling of CPP-CPG2 and CPG2-CPP Conjugates {#sec2dot5-molecules-24-04318}
-------------------------------------------------------------------

CPPs might influence the structure and function of the covalently conjugated protein \[[@B54-molecules-24-04318]\]. To deliver CPG2, the CPP segment in the conjugate should be exposed to interact with the functional groups on the plasma membrane. The CPP segment should not have any interactions with the active site of the enzyme to keep the functionality of the target protein unchanged. The conjugate should still have reasonable stereo-chemical characteristicw and low steric clashes leading to an easy folding. The I-TASSER program was used to generate PDB models. For each conjugate, models with the highest C-score value were selected and further analyzed by Ramachandran plots. In all models, the CPP domains were exposed and there were no interactions between CPPs and the active site of the CPG2 enzyme.

Residues in the most favored region and additionally allowed region of all Ramachandran plots exceeded 90%, indicating that all models were reliable \[[@B50-molecules-24-04318],[@B55-molecules-24-04318],[@B56-molecules-24-04318]\]. Compared to CPG2, *N*-terminal conjugates from peptides 9, 16, 17, 25, 54, and 62 and C-terminal conjugates from peptides 29, 39, and 69 had a higher number of residues in the most favored region of their Ramachandran plots ([Table S5](#app1-molecules-24-04318){ref-type="app"}). Therefore, it seems that the *N*-terminal conjugates of "pAntp (49--58)-CPG2", "Ala51 substitution mutant of pAntp (43--58) -CPG2", "Crot (27--39) derivative 7-CPG2", "Crot (27--39) derivative 8-CPG2", "Crot (27--39) derivative 10-CPG2", and "Crot (27--39) derivative 14-CPG2", as well as "CPG2-pVEC mutant 2", "CPG2- Ala47 substitution mutant of pAntp (43--58)", and "CPG2-Bip16" C-terminal conjugates, have easier folding than unconjugated CPG2 ([Figure 3](#molecules-24-04318-f003){ref-type="fig"} and [Table S5](#app1-molecules-24-04318){ref-type="app"}). Furthermore, it should be noted that *N*-terminal CPP-CPG2 conjugates had a significantly higher number of residues in the most favored region compared with the C-terminal isoforms ([Figure 4](#molecules-24-04318-f004){ref-type="fig"}). Accordingly, *N*-terminal conjugates have sterically higher robustness.

2.6. Thermodynamic Characteristics of CPP-CPG2 and CPG2-CPP Conjugates {#sec2dot6-molecules-24-04318}
----------------------------------------------------------------------

Thermodynamic properties play an important role in developing stable biotherapeutics \[[@B57-molecules-24-04318]\]. SCOOP server calculates thermodynamic quantities associated with the folding transition from unfolded to the native state, based on a protein's 3D structure and the host organism ([Table 6](#molecules-24-04318-t006){ref-type="table"}, [Table S6](#app1-molecules-24-04318){ref-type="app"}). The calculated parameters are co-related via the Gibbs-Helmholtz equation. According to the report of Pucci et al. \[[@B58-molecules-24-04318]\], three main strategies result in a more thermodynamically stable protein. A more negative enthalpy change (*ΔH~S~*) measured at the maximum stability temperature (*T~S~*) results in an overall decrease of *ΔG* at all temperatures. In the second strategy, the heat capacity upon folding (*ΔC~p~*) becomes less negative, which yields an increase in melting temperature (*T~m~*). The last strategy consists of an increase in *T~s~* defined at the minimum of the *ΔG(T)* curve. As a result, one can find the most stable conjugated protein at room temperature by comparing folding free energy values at room temperature (*ΔG~r~*). The conjugate's stability at higher temperatures can be associated with their corresponding *T~m~*. Based on calculated values conjugates which have higher (or even equal) *ΔG~r~* and *T~m~* compared with CPG2 are resulted from N-terminal conjugates with peptides 16, 21, 22, 36, 44, and 45 and C-terminal conjugation with peptides 16 and 63 ([Table 6](#molecules-24-04318-t006){ref-type="table"} and [Table S6](#app1-molecules-24-04318){ref-type="app"}). The position of conjugation does not significantly affect any of the thermodynamic values calculated by SCOOP.

The stability of the conjugates was also evaluated using the FoldX Suite server ([Table 7](#molecules-24-04318-t007){ref-type="table"} and [Table S7](#app1-molecules-24-04318){ref-type="app"}). According to Rahmatabadi et al. \[[@B55-molecules-24-04318]\], among the dynamic quantities calculated by FoldX Suite, four energies, including total free energy, side-chain hydrogen bonds, solvation polar, and van der Waals clashes have significant correlation with the number of amino acids in the most favored region of Ramachandran Plot; hence, affecting the stability of a protein. Amidst CPP-CPG2 conjugates, *N*-terminal conjugates derived from peptides 1, 19, 20, 21, 37, 64 and C-terminal conjugates composed of peptides 9, 32, 44, 47, 55, 56, 61, and 69 have the most negative *ΔG* values of side H bond energies. Only the *N*-terminal conjugate of "Bip 6-CPG2" has more thermodynamically stable energies across all 4 categories compared with the unconjugated CPG2. Furthermore, it was concluded that the position of conjugation does not significantly affect the calculated thermodynamic energies of CPP and CPG2 conjugates.

2.7. Prediction of the Aggregation Possibility of CPP-CPG2 and CPG2-CPP Conjugates {#sec2dot7-molecules-24-04318}
----------------------------------------------------------------------------------

It has been demonstrated that depending on the surrounding conditions and structure, proteins can form insoluble, though stable constructs composed of amyloid fibrils or amorphous aggregates \[[@B59-molecules-24-04318]\]. Protein aggregation is one of the troubles encountered in vitro and in vivo. Protein release and activity are distorted if aggregation occurs after delivery \[[@B60-molecules-24-04318],[@B61-molecules-24-04318]\]. As a result, several computational strategies are used to determine the propensity of proteins to form amyloids based on their amino acid sequence \[[@B62-molecules-24-04318],[@B63-molecules-24-04318],[@B64-molecules-24-04318]\]. Herein, we have employed two servers called Aggrescan and PASTA 2.0 to investigate if the addition of a CPP sequence to CPG2 affects the probability of protein aggregation. Aggrescan finds the number of hotspots for aggregation in a protein regarding amino acid composition, while PASTA 2.0 evaluates the chance of amyloid formations considering pairwise interactions within β-sheets. According to PASTA 2.0 calculations, there was no difference between the numbers of amyloid regions in the conjugates compared with unconjugated CPG2. However, based on Aggrescan analyses, 19 *N*-terminal conjugates and 15 C-terminal conjugates displayed 17 aggregation hotspots, whereas CPG2 itself and the rest of the conjugates had 16 aggregation hot spots. As a result, 19 *N*-terminal and 15 C-terminal conjugates might have an increased risk of aggregation than the non-fused CPG2 ([Table S8](#app1-molecules-24-04318){ref-type="app"}).

2.8. Folding Rate and Backbone Flexibility of CPP-CPG2 and CPG2-CPP Conjugates {#sec2dot8-molecules-24-04318}
------------------------------------------------------------------------------

A protein chain has to be folded into its native conformation to be functional. Therefore, the conjugates must have folding rates closer to the unconjugated CPG2. This means that the attached CPP sequence should cause a minimum disturbance in the folding of a chimera. Although conjugates showed longer folding half-times compared with CPG2, *N*-terminal conjugates from peptides 8, 10, 18, 34, 36, 59, 66, 68, and 69 and C-terminal conjugates from peptides 12, 59, 60, 61, and 64 displayed the closest half folding time to the CPG2 itself ([Table 8](#molecules-24-04318-t008){ref-type="table"}). Furthermore, regarding calculated values, *N*-terminal CPP-CPG2 conjugates displayed significantly lower half-folding time compared with C-terminal conjugates ([Figure 5](#molecules-24-04318-f005){ref-type="fig"}).

Proteins are composed of a string of amino acids, which after some non-covalent interactions fold into naturally flexible tertiary structures. The degree of flexibility is associated with a protein's function and is crucial in protein engineering and rational drug design \[[@B65-molecules-24-04318]\]. Ligand-binding sites in enzymes usually have both flexible and rigid residues. Rigid residues are associated with specificity and tightness of ligand binding, while flexibility facilitates the entrance of ligands into the binding site and can also be involved in the communication between allosteric and orthosteric binding sites \[[@B66-molecules-24-04318],[@B67-molecules-24-04318]\]. It should be noted that in any enzyme-ligand interaction, the enzyme undergoes a conformational change; therefore, variations in the enzyme's flexibility might disrupt the function. Using the Dynamine server, each conjugate was evaluated to assess if the addition of CPP sequence to CPG2 interferes with the flexibility of zinc-binding amino acids (His^89^, Asp^119^, Glu^154^, Glu^178^, and His^363^). This might intervene in the ability of CPG2 attachment to the zinc molecules that are substantial for the detoxification of MTX. No changes were observed in His^89^, Asp^119^, Glu^154^, Glu^178^, and His^363^ flexibility scores in any of the conjugates. It can be concluded that the addition of CPPs had no interference with the CPG2 ligand-binding site.

2.9. Further Analyses for In Vivo Applications {#sec2dot9-molecules-24-04318}
----------------------------------------------

In vivo administration of biotherapeutics comes with a new set of challenges. The objective of this section was to select the conjugates best suited for in vivo application ([Table 9](#molecules-24-04318-t009){ref-type="table"}).

### 2.9.1. Analyses of CPP-CPG2 and CPG2-CPP Conjugates {#sec2dot9dot1-molecules-24-04318}

Some proteins might trigger mild to acute allergic responses and fatal anaphylactic shocks. Hence, the possibility of the allergenicity of a biotherapeutic should be explored. Hypersensitivity reactions were reported only in less than 1% of patients receiving glucarpidase \[[@B27-molecules-24-04318]\]. Therefore, it should be investigated if the addition of a CPP sequence affects the probability of allergic reactions. Allergen FP V. 1.0 server evaluated CPG2 and all 140 CPP-CPG2/CPG2-CPP conjugates as probable non-allergens; thus, one can assume that the addition of these CPPs to the CPG2 sequence would not increase the enzyme's allergenicity considerably.

One of the other notable characteristics in a therapeutic is immunogenicity. If the patient's immune system recognizes a biotherapeutic as a threat, produced antibodies reduce the effectiveness of the medication after repeated use. Although glucarpidase does not result in hypersensitivity in most patients, studies have shown that anti-glucarpidase antibodies developed in 17% of patients receiving the medication for one or two doses \[[@B27-molecules-24-04318]\]. In this regard, the fused CPP sequence preferably should not increase the antigenicity of CPG2 and if possible, alleviates the immunogenicity. Assessment of CPG2 and the top 70 CPPs conjugated to *N*- and C-terminal positions showed that CPG2 and all the conjugates had immunogenicity scores above 0.4, which might act as potential antigens. The addition of CPP resulted in a decrease in immunogenicity score in most conjugates. About 66% of *N*-terminal and 60% of C-terminal conjugates had an immunogenicity score lower than that of CPG2. *N*-terminal conjugates from peptides 1, 14, 47, 48, 49 and C-terminal conjugates from peptides 14, 19, 29, 48, and 70 displayed the least immunogenicity scores. Furthermore, it was concluded that the position of conjugations does not significantly affect the immunogenicity of CPP and CPG2 conjugates.

One of the concerns for protein therapeutics is their short biological half-lives. Proteins usually have fast degradation and clearance either by kidney filtration or liver metabolism. In the case of CPP-CPG2 conjugates, intracellular proteasomes might also expedite the frequency of administration. This shows the importance of the selection of the conjugates with optimal predicted half-lives. Using the ProtLifePred server, it was shown that all C-terminal conjugates have half-lives comparable to the unconjugated CPG2, while 31% of the N-terminal conjugates had half-lives longer than the unconjugated control. The rest of the conjugates had shorter or equal half-lives compared with un-conjugated CPG2 ([Table S9](#app1-molecules-24-04318){ref-type="app"}).

### 2.9.2. Analyses of top CPPs for In Vivo Application {#sec2dot9dot2-molecules-24-04318}

Some proteins and peptides might have hemolytic toxicity towards red blood cells. Hemolysis is the premature loss of RBCs before their 120 days of the expected lifespan, which results in anemia. According to the HemoPI tool, CPPs named "Transportan 10 (TP10)" and "II" with the highest PROB scores might potentially have hemolysis effect after in vivo administration. "pVEC" mutants and "Retro - Tat (57--49)" had the lowest possibility of hemolysis. All the other CPPs had equal PROB scores relatively.

Another aspect that one should consider in the design of biotherapeutics is the undesired proinflammatory effect of proteins and peptides. For vaccines or immunotherapeutics, the ultimate goal is the activation of the immune system; however, for other proteins, proinflammatory effects such as T cell or B cell activation is undesirable. Proinflamm server checks the peptide sequence for some recognized proinflammatory epitopes. In this study, no inflammatory potential for the top 70 CPPs was detected.

As the aim of this study was to find the best candidates among experimentally validated CPPs for conjugations with CPG2, ToxinPred server was used to screen the top 70 CPPs using SVM based approach to identify toxic CPPs. Twenty percent of the top 70 CPPs were predicted to be toxic. All toxic peptides were derivatives of Crot (27--79), which originates from protein in snake venom. Unfortunately, no tool is available for the analysis of hemolytic activity and the proinflammatory effect of complete protein sequences.

2.10. Effect of Position of Conjugations on CPP-CPG2 and CPG2-CPP Conjugates {#sec2dot10-molecules-24-04318}
----------------------------------------------------------------------------

Throughout this study, the effect of position of the conjugation on the characteristics of all CPP-CPG2 and CPG2-CPP conjugates was analyzed using the unpaired t-test. The energy level of secondary structures at the 5′ mRNA's initiation translation region, robustness in the protein's 3D structures, higher helix and sheet content in the CPP region of the secondary structure after conjugation, and shorter half-folding times were all significantly improved in the N-terminal CPP-CPG2 conjugates compared with the C-terminal CPG2-CPP homologs. Regarding other features, including physiochemical properties, solubility, thermodynamic properties, probability of aggregation, backbone flexibility, allergenicity, and immunogenicity the position of conjugations was not significantly different between N- and C-terminal conjugates.

2.11. Most Promising CPP Candidates to Design CPP-CPG2/CPG2-CPP Conjugates {#sec2dot11-molecules-24-04318}
--------------------------------------------------------------------------

CPPs might influence the characteristics of the cargo protein of varying degrees. The ideal CPP for a conjugation would be the one that leads to the most favorable characteristics in the conjugate. As a result, "Bip 2", "Bip 6", "Bip 15", "pAntp (45--58)", "pAntp (46--58)", "pAntp (47--58)", "pAntp (48--58)", "pAntp (49--58)", "pAntp (51--58)", "Ala44 substitution mutant of pAntp (43--58)", "Ala52 substitution mutant of pAntp (43--58)", "Tat (48--60)", "Rev (34--50)", and "Crot (27--39) derivative 7" were CPPs with the highest desirable evaluated characteristics in N-terminal conjugation to CPG2. "Bip 1", "No.14--25", and "No.14--35" were the most promising CPPs for the C-terminus ([Table S10](#app1-molecules-24-04318){ref-type="app"}). These seventeen CPP candidates can be categorized into five families:

(1) HIV-Tat and Its Derivatives:

Tat peptide is derived from the transcription transactivator protein of the HIV-1 virus. Tat has been successfully used in conjugation with a variety of molecules such as peptides, proteins, liposomes, nanoparticles, and nucleic acids \[[@B68-molecules-24-04318]\]. In this study, "Tat (48--60)" and one of its derivatives "Rev (34--50)" are on our final candidate list. This is in agreement with our recent findings, wherein we have demonstrated experimentally the efficient intracellular delivery of CPG2 conjugated to the TAT peptide \[[@B28-molecules-24-04318]\]. Both native and denatured forms of the enzyme transduced efficiently into the HepG2 cells in a concentration- and time-dependent manner. We have observed that in cells pretreated with TAT-CPG2 protein, the viability in the presence of MTX increased up to 98.63% compared with the control group, which had a viability of about 44.37%. Hence, TAT-CPG2 was introduced as a strong protector of HepG2 cells against MTX-induced cell death.

(2) Penetratin Derivatives:

After the discovery of Tat, the penetratin peptide, which is derived from the amphiphilic *Drosophila* Antennapedia homeodomain (amino acids 43--58 of the homeodomain) was introduced as a CPP \[[@B69-molecules-24-04318]\]. Currently, penetratin based therapeutics are being examined in vivo \[[@B70-molecules-24-04318]\]. Eight CPPs from our final candidates including "pAntp (45--58)", "pAntp (46--58)", "pAntp (47--58)", "pAntp (48--58)", "pAntp (49--58)", "pAntp (51--58)", "Ala44 substitution mutant of pAntp (43--58)", and "Ala52 substitution mutant of pAntp (43--58)" in the N-terminal conjugates are from this family.

(3) Crot (27--39) Derivatives:

Crotamin, a toxin found in snake venom, has two nuclear localization domains, named crot (2--18) and crot (27--39). Various derivatives of Crot (27--39) CPP with the original amino acid sequence of "KMDCRWRWKCCKK" are developed using amino acid substitution, deletion, or addition \[[@B49-molecules-24-04318]\]. "Crot (27--39) derivative 7" from our candidate list belongs to this family.

(4) Cell-Penetrating Pentapeptides (CPP5s):

This group is designed according to the Bax-binding domain of Ku70 protein. Ku70 exerts cytoprotective effect by binding to Bax (a pro-apoptotic protein) and blocking its activation. Several cell-penetrating anti-apoptotic pentamer peptide sequences were designed based on the Bax-binding domain of Ku70. Subsequently, other CPP5s were developed by scrambling the sequence \[[@B71-molecules-24-04318],[@B72-molecules-24-04318]\]. All five CPP5s are on our final candidates' list, including "Bip 2", "Bip 6" and "Bip 15" in the N-terminal conjugates, as well as "Bip 1", in the C-terminal conjugates to CPG2. Among these CPP5s, "Bip 1", "Bip 2", and "Bip 6" have cytoprotective properties, while "Bip 15" is without any cytoprotective effects \[[@B37-molecules-24-04318],[@B73-molecules-24-04318]\]. Therefore, for the elimination of MTX and cytoprotective purposes, "Bip 1", "Bip 2", and "Bip6" might have further beneficial effects in conjugation to CPG2.

(5) Peptide No. 14 Derivatives:

This family of peptides was invented using an in vitro virus library to design CPPs with high transduction efficacy. These CPPs displayed higher uptake efficacy compared with TAT in some cell lines \[[@B36-molecules-24-04318]\]. Furthermore, these peptides are sequentially similar to tumor lineage-homing cell- penetrating peptides \[[@B35-molecules-24-04318]\]. Peptides named "No.14--25" and "No.14--35" from our most promising candidates in C-terminal conjugates belongs to this group of peptides.

2.12. Analysis of Susceptibility to Human Proteases {#sec2dot12-molecules-24-04318}
---------------------------------------------------

Proteases are a group of enzymes that can cleave the peptide backbone of their target proteins. Some proteases are only able to recognize and cleave particular amino acid sequences known as cleavage sites. Proteolytic degradation of peptides and protein-based drugs is one of the major complications on the way of achieving optimum systemic administration of therapeutics \[[@B74-molecules-24-04318]\]. Glucarpidase, like other peptide and protein-based biotherapeutics, is prone to proteolytic degradation. Although its stability in the blood is high enough to eliminate high concentrations of blood MTX, this might not be enough for successful application in ADEPT \[[@B75-molecules-24-04318]\]. Therefore, several strategies have been applied to increase the resistance of glucarpidase to proteolytic enzymes, such as PEGylation, fusion with human serum albumin \[[@B76-molecules-24-04318],[@B77-molecules-24-04318]\], and circular permutations \[[@B75-molecules-24-04318]\].

Using the Prosperous server, CPG2 and the most promising conjugates (17 final conjugates) were evaluated against human proteases ([Tables S11 and S12](#app1-molecules-24-04318){ref-type="app"}). The protease susceptibility of the conjugates is similar to the unconjugated CPG2, except for "Rev (34--50)-CPG2" that had a significant chance of being cleaved by "Kallikrein related peptidase 5", while CPG2 and other CPP-CPG2 conjugates are expected to be resistant in the presence of the above-mentioned peptidase. It was observed that in some instances CPP-CPG2 conjugates had higher numbers of cleavage sites compared with CPG2 due to the addition of CPP sequence. However, the significant increase in cleavage sites has been observed for those proteases that target the unconjugated CPG2 even before the conjugation. Furthermore, some enzymes, for example, proprotein convertase 1 and 2, furin, and thrombin were able to cut inside the CPP sequence conjugated to CPG2. It could also be observed that the conjugation of CPP to CPG2 did not significantly decrease the protease susceptibility of CPG2.

2.13. Limitations of the Current Study {#sec2dot13-molecules-24-04318}
--------------------------------------

The mechanism of CPP translocation across plasma membranes is highly dependent on the type of cell line, the concentration of CPP, and the type of cargo \[[@B78-molecules-24-04318]\]. Several CPPs can directly pass through the plasma membrane \[[@B79-molecules-24-04318]\]; however, some others---especially those that are conjugated to macromolecules---penetrate through the endocytosis pathway. Endocytosis might result in the entrapment of the conjugate inside the endocytic organelles before arrival to the cytoplasmic or nuclear target \[[@B80-molecules-24-04318]\]. Hence, the entrapment of CPPs and the corresponding conjugates inside the endosome is one of the limitations in the current computational and experimental studies. Although a bioinformatics method for the assessment of possible entrapment of CPP-protein conjugates is not available yet, using multivalent CPPs or CPP conjugation to a pH-Dependent Membrane Active Peptide (PMAP) are recommended to resolve inadequate CPP-protein endosomal release issues \[[@B79-molecules-24-04318]\]. However, it was promising that in our experimental study conducted on the N-terminal conjugate of TAT-CPG2, the release of CPP-cargo conjugates from endosomes was high to display adequate pharmacological responses \[[@B28-molecules-24-04318]\].

3. Materials and Methods {#sec3-molecules-24-04318}
========================

3.1. Primary Dataset Collection {#sec3dot1-molecules-24-04318}
-------------------------------

Sequences of CPPs were retrieved from CPP site 2.0 (<http://crdd.osdd.net/raghava/cppsite/>), which keeps the records of experimentally validated CPPs \[[@B17-molecules-24-04318]\]. After excluding cyclic peptides and CPPs that had un-natural residues or amino acids with D-conformations, 1155 unique CPPs remained. Although some of the excluded CPPs---CPPs with unnatural or D-conformation residues and cyclic CPPs---have shown promising results in experimental studies \[[@B81-molecules-24-04318],[@B82-molecules-24-04318],[@B83-molecules-24-04318]\], current computational web servers are unable to analyze these sequences. Mature CPG2 amino acid sequence from *Pseudomonas* sp. strain RS-16 was retrieved from Uniprot (Uniprot ID \# P06621) to build protein conjugates. The nucleotide sequence of the *cpg2* gene was then codon-optimized by the codon usage wrangler server (<https://www.mrc-lmb.com.ac.uk/ms/methods/codon.html>).

3.2. Penetration Prediction of CPPs {#sec3dot2-molecules-24-04318}
-----------------------------------

The uptake efficiency and respective prediction confidence for all 1155 CPPs was predicted using the CPPred-RF server (<http://server.malab.cn/CPPred-RF/>) \[[@B84-molecules-24-04318]\]. Results of CPPred-RF sever analysis was narrowed down to 70 CPP candidates, which have the highest uptake efficiency with the prediction confidence of 0.9 or above.

3.3. mRNA Secondary Structure Prediction of cpg2 and cpp-cpg2/cpg2-cpp Conjugates {#sec3dot3-molecules-24-04318}
---------------------------------------------------------------------------------

The nucleotide sequences of *cpg2* and top 70 *cpps* conjugated to either N- or C-terminus of *cpg2* gene in PET 14b expression vector (*cpp-cpg2*-pET14b) were used to determine the secondary structure and the minimum free energy of 5′-mRNA translation initiation region using the mfold online server (<http://unafold.rna.albany.edu/?q=DINAMelt/Quickfold>) \[[@B85-molecules-24-04318]\]. To construct the N-terminal conjugates, 30 bases upstream of the start codon in PET 14b were fused to 30 initial bases of *cpps* linked to the codon-optimized *cpg2* gene. For the C-terminal conjugates, 30 bases upstream of the start codon were directly connected to the codon-optimized *cpg2*. PET 14b was selected due to our recent success in the expression of *cpg2* and *tat*- *cpg2* fusion constructs \[[@B28-molecules-24-04318]\].

3.4. Prediction of Physiochemical Properties of CPPs and CPP-CPG2/CPG2-CPP Conjugates {#sec3dot4-molecules-24-04318}
-------------------------------------------------------------------------------------

Physiochemical properties of CPG2, N-terminal CPP-CPG2 and C-terminal CPG2-CPP conjugates, as well as the top 70 CPPs alone, including molecular weight (Mw), isoelectric point (pI), instability index, GRAVY, and aliphatic index were calculated using ProtParam tool (<http://web.expasy.org/protparam/>) \[[@B86-molecules-24-04318]\].

3.5. Solubility Prediction of CPG2 and CPP-CPG2/CPG2-CPP Conjugates {#sec3dot5-molecules-24-04318}
-------------------------------------------------------------------

The solubility of CPG2 and the top 70 CPPs linked to either *N*- or C-terminus of CPG2 was calculated using the ccSol server (<http://s.tartaglialab.com/page/ccsol_group>) \[[@B87-molecules-24-04318]\].

3.6. Modeling 3D Structures of CPG2 and CPP-CPG2/CPG2-CPP Conjugates {#sec3dot6-molecules-24-04318}
--------------------------------------------------------------------

FASTA sequences of CPG2 and the top 70 CPPs as *N*- and C-terminal conjugates to CPG2 were submitted to the Iterative Threading ASSEmbly Refinement (I-TASSER) program (<https://zhanglab.ccmb.med.umich.edu/I-TASSER/>) \[[@B88-molecules-24-04318],[@B89-molecules-24-04318]\]. The most confident models (highest C-score value) derived from I-TASSER were uploaded to the PDBsum Generate EMBL-EBI (<https://www.ebi.ac.uk/thornton-srv/databases/pdbsum/Generate.html>) \[[@B90-molecules-24-04318]\]. Subsequently, PDBsum (<http://www.ebi.ac.uk/thornton-srv/databases/pdbsum>) generated a Ramachandran plot for each model \[[@B91-molecules-24-04318]\]. Ramachandran plots were analyzed for the most favored and additional allowed conformational regions. CPPs' secondary structures after their conjugation to CPG2 in the models also were noted.

3.7. Thermodynamic Quantities of CPG2 and CPP-CPG2/CPG2-CPP Conjugates {#sec3dot7-molecules-24-04318}
----------------------------------------------------------------------

PDB models of CPG2 and CPP-CPG2 N- and C-terminal conjugates were submitted to the SCOOP (<http://babylone.ulb.ac.be/SCooP/k_query.php>) \[[@B92-molecules-24-04318]\] and FoldX (<http://foldx.embl.de/>) web servers \[[@B93-molecules-24-04318]\]. SCOOP predicts the melting temperature (*T~m~*), changes in enthalpy (*ΔH~m~*), heat capacity upon folding (*ΔC~p~*), and the folding free energy at room temperature (*ΔG~r~*). Using FoldX Suite, some of the stability features including total free energy, side-chain hydrogen bond (Side H bond), solvation polar (solp), and Van der Waals clashes (VdW clash) energies were calculated.

3.8. Prediction of Aggregation Possibility of CPG2 and CPP-CPG2/CPG2-CPP Conjugates {#sec3dot8-molecules-24-04318}
-----------------------------------------------------------------------------------

FASTA sequences of CPG2 and the top 70 CPPs linked to the N- and C-terminus of CPG2 were submitted to PASTA 2.0 (<http://protein.bio.unipd.it/pasta2/>) \[[@B94-molecules-24-04318]\] and Aggrescan (<http://bioinf.uab.es/aggrescan/>) \[[@B63-molecules-24-04318]\] servers to compare aggregation possibility of conjugated *versus* un-conjugated CPG2 protein. PASTA 2.0 analyzes segments that are more likely to form fibrillar aggregates, and Aggrescan predicts the number of hot spots for aggregation in a sequence.

3.9. Folding Rate of CPG2 and CPP-CPG2/CPG2-CPP Conjugates {#sec3dot9-molecules-24-04318}
----------------------------------------------------------

Sequences of CPG2 and the top 70 CPPs linked to the N- and C-terminus of CPG2 were submitted to the Foldrate server (<http://www.csbio.sjtu.edu.cn/bioinf/FoldRate/>) \[[@B95-molecules-24-04318]\]. Foldrate provides an estimation on the time needed for proteins to fold into their tertiary structure by predicting ln(*K*~f~) constant of folding and half-folding time.

3.10. Backbone Flexibility of CPG2 and CPP-CPG2/CPG2-CPP Conjugates {#sec3dot10-molecules-24-04318}
-------------------------------------------------------------------

Amino acid sequences of CPG2 and both N- and C-terminal conjugates of the top 70 CPPs and CPG2 were analyzed using the DynaMine server (<http://dynamine.ibsquare.be/>) \[[@B96-molecules-24-04318]\]. DynaMine predicts the flexibility of each amino acid in a protein sequence by attributing values between 0--1 to each residue. Zero accounts for complete flexibility and 1 for complete rigidity.

3.11. Further Analyses for In Vivo Application {#sec3dot11-molecules-24-04318}
----------------------------------------------

### 3.11.1. Analyses of CPP-CPG2 and CPG2-CPP Conjugates {#sec3dot11dot1-molecules-24-04318}

Sequences of 70 top CPP-CPG2 N-terminal and CPG2-CPP C-terminal conjugates were analyzed using AllergenFP V 1.0 (<http://ddg-pharmfac.net/AllergenFP/>) \[[@B97-molecules-24-04318]\] to predict their potential allergenicity. Sequences of both *N*- and C-terminal conjugates of the top 70 CPPs and CPG2 were analyzed for potential immunogenicity by the VaxiJen V2.0 server (<http://www.ddgpharmfac.net/vaxijen/VaxiJen/VaxiJen.html>) \[[@B98-molecules-24-04318]\] considering bacteria as selected target organism. The half-life of CPG2 conjugated to the top 70 CPPs (both N- and C-terminal conjugates) was calculated using the ProtLifePred server (<http://protein-n-end-rule.leadhoster.com/>) in *E. coli* as the expression system. ProtLifePred server estimates the half-life of protein sequences based on the N-end rule considering ubiquitination \[[@B99-molecules-24-04318],[@B100-molecules-24-04318]\].

### 3.11.2. Analyses of CPPs {#sec3dot11dot2-molecules-24-04318}

The top 70 CPPs were analyzed for their possible RBC lysis effect after in vivo administration by the HemoPI server (<http://crdd.osdd.net/raghava/hemopi/>) \[[@B101-molecules-24-04318]\]. HemoPI server analyses submitted sequences using SVM based approach to predict their hemolysis potency by assigning each query a PROB score that ranges between 0-1. Zero is an indication of the lowest possibility of being hemolytic. In this study, the PROB score was set on 0.5 to determine hemolytic toxicity for each CPP. Potential toxicity of the top 70 CPPs was evaluated by ToxinPred server (<http://crdd.osdd.net/raghava/toxinpred/multi_submit.php>) \[[@B102-molecules-24-04318]\], using the server's default threshold (zero). Top 70 CPPs were checked for pro-inflammatory effect using the ProInflam server (<http://metagenomics.iiserb.ac.in/proinflam/index.html>) \[[@B103-molecules-24-04318]\].

3.12. Evaluation of CPP-CPG2/CPG2-CPP Conjugates Susceptibility to Human Proteases {#sec3dot12-molecules-24-04318}
----------------------------------------------------------------------------------

The susceptibility of the most promising CPP-CPG2 and CPG2-CPP conjugates to human proteases was evaluated using the Prosperous web server (<http://prosperous.erc.monash.edu/>) \[[@B104-molecules-24-04318],[@B105-molecules-24-04318]\]. Out of 90 proteases available on the Prosperous server, 51 were human proteases according to MEROPS: the peptidase database \[[@B106-molecules-24-04318]\]. These human proteases are categorized into four families, including aspartic proteases like cathespsin D and E, cysteine proteases like caspase 1 and 3, metalloproteases like matrix metallopeptidase 1,2, 3, and serine proteases like thrombin and plasmin.

Prosperous assigns each cleavage site a probability score between 0.0 and 1.0. Zero is considered as the lowest possibility and 1.0 is estimated as the highest possibility of a position being recognized and cleaved by a protease. In this analysis, the FASTA sequences of CPG2 and 17 most promising CPP-CPG2/CPG2-CPP conjugates were submitted to Prosperous. A probability score of 0.700 and higher was considered significant for the susceptibility to human proteases. An overview of analyses employed in this study is shown as a bioinformatics flowchart below ([Scheme 1](#molecules-24-04318-sch001){ref-type="scheme"}).

3.13. Statistical Analyses {#sec3dot13-molecules-24-04318}
--------------------------

Unpaired t-test was used to test the significance between N-terminal (CPP-CPG2) and C-terminal (CPG2-CPP) values using GraphPad Prism 8 software (GraphPad Software, Inc. San Diego, CA, USA). *p* \< 0.05 indicated statistical significance.

4. Conclusions {#sec4-molecules-24-04318}
==============

Within this study, characterizing a high number of CPPs highlighted crucial factors necessary for the rational design of a CPP-protein chimera. This study presented a bioinformatics workflow applicable as a comprehensive approach useful to select CPP-cargo constructs for any therapeutic application. The addition of CPPs resulted in a higher probability of translation of mRNA into protein in about 74% of the *N*-terminal conjugates. Structurally more than 70% of the CPPs had α-helix or β-sheet conformations in their secondary structure after conjugations, which results in higher penetration than for non-fused cargo. Addition of CPPs did not cause any significant negative changes regarding the stability of the target protein (thermodynamic stability and resistance to human proteases). Except for a few CPPs which might result in higher aggregation of the chimera, analysis of the physiochemical characteristics showed that the dominant number of CPPs linked to the cargo did not have any negative influence on the properties. Conjugation of CPPs did not negatively interfere with the solubility, even improved it. Computational analyses showed that allergenicity is not affected negatively and does not lead to limitations for injectable formulations. Flexibility analysis showed that in most conjugates, the addition of CPPs caused no major alterations in the overall enzyme flexibility. In all conjugates, the flexibility of the ligand-binding site after the addition of a CPP remained unchanged. However, stronger servers are needed for evaluation of the RBC hemolysis and pro-inflammatory effect of the peptide-protein conjugate. Concerning the position of conjugations, the N-terminal linkage is preferred for the construction of CPP-CPG2 conjugates than the C-terminus CPG2-CPP homologs. The approach presented in this investigation is not limited to the CPP-glucarpidase case study but is generally applicable to any CPP-protein conjugate design. Hence, our study provides a platform for further in vitro and in vivo investigations, which should be considered regarding the advantages of computational analyses before designing any covalently conjugated CPP-protein construct.
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![The percentage of distribution of amino acids with helix and sheet configuration in the N-terminal (CPP-CPG2) and C-terminal (CPG2-CPP) conjugates.](molecules-24-04318-g001){#molecules-24-04318-f001}

![mRNA initiation translation region secondary structures and location of the start codon (indicated by arrows) for two conjugates and CPG2. (**a**) "R9-CPG2 + PET 14b" has a higher *ΔG* value compared with CPG2 and the start codon is exposed (**b**) "Transportan 10-CPG2 + PET 14b" has a lower *ΔG* value compared with CPG2 and the start codon is not exposed. (**c**) Control CPG2 + PET 14b: start codon is not exposed.](molecules-24-04318-g002){#molecules-24-04318-f002}

![3D models of (**a**) CPG2 and (**b**) "Ala51 substitution mutant of pAntp (43-58)" conjugated to the *N*-terminal position of CPG2 and their respective Ramachandran plots.](molecules-24-04318-g003){#molecules-24-04318-f003}

![Distribution of percentage of amino acids present in the most favored region of Ramachandran plot across N- (CPP-CPG2) and C-terminal (CPG2-CPP) conjugates.](molecules-24-04318-g004){#molecules-24-04318-f004}
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![A summary of the proposed workflow to select the most promising CPPs in conjugation with a protein.](molecules-24-04318-sch001){#molecules-24-04318-sch001}

molecules-24-04318-t001_Table 1

###### 

Results of CPPred-RF server analysis for 70 cell-penetrating peptides (CPPs) that had high uptake efficiency with prediction confidence of above 0.9.

  Peptide No.   CPPs' Names                                   Amino Acid Sequence      Cell-Penetrating or Not   Prediction Confidence ^1^   Uptake Efficiency   Prediction Confidence ^2^
  ------------- --------------------------------------------- ------------------------ ------------------------- --------------------------- ------------------- ---------------------------
  1             Transportan 10 (TP10)                         AGYLLGKINLKALAALAKKIL    Cell-penetrating          0.98                        High                1.00
  2             Ala43 substitution mutant of pAntp (43--58)   AQIKIWFQNRRMKWKK         Cell-penetrating          0.95                        High                0.96
  3             Crot (27--39) derivative 1                    CRFRFKCCKK               Cell-penetrating          0.96                        High                0.98
  4             Crot (27--39) derivative 2                    CRFRWKCCKK               Cell-penetrating          0.96                        High                0.99
  5             Crot (27--39) derivative 3                    CRWRFKCCKK               Cell-penetrating          0.96                        High                1.00
  6             CyLoP--1                                      CRWRWKCCKK               Cell-penetrating          0.95                        High                1.00
  7             Crot (27--39) derivative 4                    CRWRWKCGCKK              Cell-penetrating          0.92                        High                0.99
  8             Crot (27--39) derivative 5                    DCRWRWKCCKK              Cell-penetrating          0.82                        High                0.99
  9             pAntp (49--58)                                FQNRRMKWKK               Cell-penetrating          0.84                        High                0.91
  10            Tat (48--60)                                  GRKKRRQRRRPPQ            Cell-penetrating          0.97                        High                0.94
  11            pAntp (45--58)                                IKIWFQNRRMKWKK           Cell-penetrating          0.93                        High                0.91
  12            Bip15                                         IPMLK                    Cell-penetrating          0.56                        High                0.92
  13            pAntp (47--58)                                IWFQNRRMKWKK             Cell-penetrating          0.89                        High                0.97
  14            II                                            KALAALLKKLAKLLAALK       Cell-penetrating          1.00                        High                0.93
  15            Crot (27--39) derivative 6                    KCCKWRWRCK               Cell-penetrating          0.95                        High                0.94
  16            Crot (27--39) derivative 7                    KCGCRWRWKCGCKK           Cell-penetrating          0.95                        High                0.90
  17            Crot (27--39) derivative 8                    KCRWRWKCCKK              Cell-penetrating          0.95                        High                0.98
  18            Crot (27--39) derivative 9                    KDCRWRWKCCKK             Cell-penetrating          0.78                        High                0.99
  19            pAntp (46--58)                                KIWFQNRRMKWKK            Cell-penetrating          0.93                        High                0.96
  20            7                                             KLWMRWWSPTTRRYG          Cell-penetrating          0.98                        High                0.93
  21            No.14--2                                      KLWMRWYSATTRRYG          Cell-penetrating          0.98                        High                0.97
  22            No.14                                         KLWMRWYSPTTRRYG          Cell-penetrating          0.98                        High                0.96
  23            No.14--7                                      KLWMRWYSPWTRRYG          Cell-penetrating          0.96                        High                0.92
  24            Crot (27--39)                                 KMDCRWRWKCCKK            Cell-penetrating          0.80                        High                0.94
  25            Crot (27--39) derivative 10                   KMDCRWRWKCKK             Cell-penetrating          0.78                        High                0.95
  26            Crot (27--39) derivative 11                   KMDCRWRWKCSKK            Cell-penetrating          0.82                        High                0.95
  27            Crot (27--39) derivative 12                   KMDCRWRWKSCKK            Cell-penetrating          0.83                        High                0.95
  28            pVEC mutant 1                                 LLIILRARIRKQAHAHSK       Cell-penetrating          0.98                        High                0.90
  29            pVEC mutant 2                                 LLIILRRAIRKQAHAHSK       Cell-penetrating          0.98                        High                0.95
  30            pVEC mutant 3                                 LLIILRRRIRAQAHAHSK       Cell-penetrating          0.98                        High                0.94
  31            Crot (27--39) derivative 13                   MDCRWRWKCCKK             Cell-penetrating          0.79                        High                0.93
  32            ARF (1-22)                                    MVRRFLVTLRIRRACGPPRVRV   Cell-penetrating          0.88                        High                0.93
  33            M918                                          MVTVLFRRLRIRRACGPPRVRV   Cell-penetrating          0.90                        High                0.94
  34            pAntp (51--58)                                NRRMKWKK                 Cell-penetrating          0.90                        High                0.91
  35            pAntp (44--58)                                QIKIWFQNRRMKWKK          Cell-penetrating          0.96                        High                0.92
  36            pAntp (50--8)                                 QNRRMKWKK                Cell-penetrating          0.88                        High                0.96
  37            Ala44 substitution mutant of pAntp (43--58)   RAIKIWFQNRRMKWKK         Cell-penetrating          1.00                        High                0.99
  38            PDX -1-PTD                                    RHIKIWFQNRRMKWKK         Cell-penetrating          0.99                        High                0.92
  39            No.14--25                                     RLFMRFYSPTTRRYG          Cell-penetrating          0.95                        High                0.93
  40            No.14--17                                     RLWMRWASPTTRRYG          Cell-penetrating          0.99                        High                0.96
  41            No.14--18                                     RLWMRWYAPTTRRYG          Cell-penetrating          0.98                        High                0.98
  42            No.14--20                                     RLWMRWYSPATRRYG          Cell-penetrating          0.99                        High                1.00
  43            No.14--21                                     RLWMRWYSPTARRYG          Cell-penetrating          0.99                        High                1.00
  44            No.14--35                                     RLWMRWYSPTTRRYA          Cell-penetrating          0.98                        High                0.98
  45            No.14--1                                      RLWMRWYSPTTRRYG          Cell-penetrating          0.99                        High                0.98
  46            30                                            RLYMRYYSPTTRRYG          Cell-penetrating          0.97                        High                0.93
  47            Ala45 substitution mutant of pAntp (43--58)   RQAKIWFQNRRMKWKK         Cell-penetrating          0.98                        High                0.98
  48            Ala46 substitution mutant of pAntp (43--58)   RQIAIWFQNRRMKWKK         Cell-penetrating          0.98                        High                0.91
  49            Ala47 substitution mutant of pAntp (43--58)   RQIKAWFQNRRMKWKK         Cell-penetrating          0.99                        High                0.99
  50            Ala48 substitution mutant of pAntp (43--58)   RQIKIAFQNRRMKWKK         Cell-penetrating          1.00                        High                0.94
  51            Ala49 substitution mutant of pAntp (43--58)   RQIKIWAQNRRMKWKK         Cell-penetrating          1.00                        High                0.98
  52            Ala50 substitution mutant of pAntp (43--58)   RQIKIWFANRRMKWKK         Cell-penetrating          0.99                        High                0.99
  53            pAntpHD (Pro50)                               RQIKIWFPNRRMKWKK         Cell-penetrating          0.99                        High                0.96
  54            Ala51 substitution mutant of pAntp (43--58)   RQIKIWFQARRMKWKK         Cell-penetrating          0.99                        High                0.94
  55            Ala52 substitution mutant of pAntp (43--58)   RQIKIWFQNARMKWKK         Cell-penetrating          0.95                        High                0.92
  56            Met-Arg                                       RQIKIWFQNMRRKWKK         Cell-penetrating          1.00                        High                0.93
  57            Ala54 substitution mutant of pAntp (43--58)   RQIKIWFQNRRAKWKK         Cell-penetrating          0.99                        High                0.97
  58            Penetratin                                    RQIKIWFQNRRMKWKK         Cell-penetrating          1.00                        High                0.97
  59            Retro - Tat (57--49)                          RRRQRRKKR                Cell-penetrating          1.00                        High                0.90
  60            R6                                            RRRRRR                   Cell-penetrating          1.00                        High                0.91
  61            R9                                            RRRRRRRRR                Cell-penetrating          1.00                        High                0.91
  62            Crot (27--39) derivative 14                   RWRWKCCKK                Cell-penetrating          0.91                        High                0.97
  63            Crot (27--39) derivative 15                   SRWRWKCCKK               Cell-penetrating          0.94                        High                0.93
  64            Rev (34--50)                                  TRQARRNRRRRWRERQR        Cell-penetrating          0.98                        High                0.90
  65            HIV-1 Rev (34--50)                            TRQARRNRRRRWRERQRGC      Cell-penetrating          0.96                        High                0.90
  66            Bip6                                          VPALK                    Cell-penetrating          0.74                        High                0.96
  67            Bip1                                          VPMLK                    Cell-penetrating          0.57                        High                0.96
  68            Bip2                                          VPTLK                    Cell-penetrating          0.67                        High                0.99
  69            Bip16                                         VPTLQ                    Cell-penetrating          0.60                        High                0.91
  70            pAntp (48--58)                                WFQNRRMKWKK              Cell-penetrating          0.84                        High                0.97

^1^ Prediction confidence of cell penetration. ^2^ Prediction confidence of uptake efficiency.

molecules-24-04318-t002_Table 2

###### 

Experimental data on the uptake efficiency of top 70 CPPs.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Category                                                           Names of CPPs                                         Experimental Uptake Efficiency                                         References
  ------------------------------------------------------------------ ----------------------------------------------------- ---------------------------------------------------------------------- ---------------------------------------------------------
  **Crot (27--39) and its derivatives**                              CyLoP-1                                               High, higher than D-Tat peptide, penetratin, and D-R8                  \[[@B29-molecules-24-04318]\]

  Crot (27--39)                                                      78% of CyLoP1                                                                                                                

  Crot (27--39) derivative 1                                         63% of CyLoP1                                                                                                                

  Crot (27--39) derivative 2                                         66% of CyLoP1                                                                                                                

  Crot (27--39) derivative 3                                         61% of CyLoP1                                                                                                                

  Crot (27--39) derivative 4                                         59% of CyLoP1                                                                                                                

  Crot (27--39) derivative 5                                         47% of CyLoP1                                                                                                                

  Crot (27--39) derivative 6                                         42% of CyLoP1                                                                                                                

  Crot (27--39) derivative 7                                         75% of CyLoP1                                                                                                                

  Crot (27--39) derivative 8                                         39% of CyLoP1                                                                                                                

  Crot (27--39) derivative 9                                         26% of CyLoP1                                                                                                                

  Crot (27--39) derivative 10                                        79% of CyLoP1                                                                                                                

  Crot (27--39) derivative 11                                        58% of CyLoP1                                                                                                                

  Crot (27--39) derivative 12                                        29% of CyLoP1                                                                                                                

  Crot (27--39) derivative 13                                        83% of CyLoP1                                                                                                                

  Crot (27--39) derivative 14                                        37% of CyLoP1                                                                                                                

  Crot (27--39) derivative 15                                        46% of CyLoP1                                                                                                                

  **Penetratin and its derivatives**                                 Penetratin/pAntp (43--58)                             Lower than polyarginines but higher than Tat peptide and transportan   \[[@B30-molecules-24-04318]\]

  pAntp (44--58)                                                     85% of pAntp (43--58)                                 \[[@B31-molecules-24-04318]\]                                          

  pAntp (45--58)                                                     95% of pAntp (43--58)                                                                                                        

  pAntp (46--58)                                                     65% of pAntp (43--58)                                                                                                        

  pAntp (47--58)                                                     50% of pAntp (43--58)                                                                                                        

  pAntp (48--58)                                                     55% of pAntp (43--58)                                                                                                        

  pAntp (49--58)                                                     65% of pAntp (43--58)                                                                                                        

  pAntp (50--58)                                                     60% of pAntp (43--58)                                                                                                        

  pAntp (51--58)                                                     60% of pAntp (43--58)                                                                                                        

  Ala43 substitution mutant of pAntp (43--58)                        90% of pAntp (43--58)                                                                                                        

  Ala44 substitution mutant of pAntp (43--58)                        65% of (pAntp) (43--58)                                                                                                      

  Ala45 substitution mutant of pAntp (43--58)                        80% of pAntp (43--58)                                                                                                        

  Ala46 substitution mutant of pAntp (43--58)                        50% of pAntp (43--58)                                                                                                        

  Ala47 substitution mutant of pAntp (43--58)                        55% of pAntp (43--58)                                                                                                        

  Ala48 substitution mutant of pAntp (43--58)                        65% of pAntp (43--58)                                                                                                        

  Ala49 substitution mutant of pAntp (43--58)                        90% of pAntp (43--58)                                                                                                        

  Ala50 substitution mutant of pAntp (43--58)                        90% of pAntp (43--58)                                                                                                        

  Ala51 substitution mutant of pAntp (43--58)                        60% of pAntp (43--58)                                                                                                        

  Ala52 substitution mutant of pAntp (43--58)                        45% of pAntp (43--58)                                                                                                        

  Ala54 substitution mutant of pAntp (43--58)                        90% of pAntp (43--58)                                                                                                        

  Met-Arg                                                            Not available                                         \[[@B32-molecules-24-04318]\]                                          

  pAntpHD (Pro50)                                                    High\                                                 \[[@B33-molecules-24-04318]\]                                          
                                                                     Comparable to pAntp (43--58)                                                                                                 

  **CPP derived from PDX-1 protein**                                 PDX-1-PTD                                             Not available                                                          \[[@B34-molecules-24-04318]\]

  **Tumor lineage-homing CPPs**                                      7                                                     Not available                                                          \[[@B35-molecules-24-04318]\]

  **Peptide 14 and its derivatives**                                 No.14                                                 Higher than Tat peptide                                                \[[@B36-molecules-24-04318]\]

  No.14--1                                                           Higher than Tat and peptide No. 14                                                                                           

  No.14--2                                                           Higher than Tat peptide                                                                                                      

  No.14--7                                                           Higher than Tat and peptide No. 14                                                                                           

  No.14--17                                                          Equal to Peptide No. 14                                                                                                      

  No.14--18                                                          Higher than Peptide 14 and equal to peptide 14--1                                                                            

  No.14--20                                                          Higher than Peptide 14 and equal to peptide 14--1                                                                            

  No.14--21                                                          Higher than Peptide 14 and equal to peptide 14--1                                                                            

  No.14--25                                                          Equal to peptide 14                                                                                                          

  No.14--30                                                          Higher than peptide 14 and lower than peptide 14--1                                                                          

  No.14--35                                                          Higher than Peptide 14 and equal to peptide 14--1                                                                            

  **Cell-penetrating penta peptides**\                               Bip1                                                  High\                                                                  \[[@B37-molecules-24-04318]\]
  **(CPP5s)**                                                                                                              About 97% of KLPVM                                                     

  Bip2                                                               About 61% of KLPVM)                                                                                                          

  Bip6                                                               About 71% of KLPVM                                                                                                           

  Bip15                                                              Not available                                                                                                                

  Bip16                                                              About 70% KLPVM                                                                                                              

  **pVEC (CPP derived from murine vascular endothelial cadherin)**   pVEC mutant 1                                         Comparable to pVEC                                                     \[[@B38-molecules-24-04318]\]

  pVEC mutant 2                                                      Higher than pVEC                                                                                                             

  pVEC mutant 3                                                      Comparable to pVEC                                                                                                           

  **Tat peptide and its derivatives**                                Tat (48--60)                                          High\                                                                  \[[@B30-molecules-24-04318],[@B39-molecules-24-04318]\]
                                                                                                                           Lower than polyarginine and penetratin but equal to transportan        

  Rev (34--50)                                                       High\                                                 \[[@B40-molecules-24-04318]\]                                          
                                                                     Comparable to Tat (48--60)                                                                                                   

  HIV-1 Rev (34--50)                                                 2.5-6.6 times more than Tat (48--60)                  \[[@B41-molecules-24-04318]\]                                          

  Retro - Tat (57--49)                                               High\                                                 \[[@B42-molecules-24-04318]\]                                          
                                                                     Compared to Tat (49--57)                                                                                                     

  **Polyarginines**                                                  R6                                                    Lower than R9                                                          \[[@B42-molecules-24-04318]\]

  R9                                                                 High                                                                                                                         

  **Transportan peptide derivative**                                 Transportan 10 (TP10)                                 High                                                                   \[[@B43-molecules-24-04318]\]

  **CPPs derived from tumor suppressor protein p14ARF**              ARF(1--22)                                            High\                                                                  \[[@B43-molecules-24-04318]\]
                                                                                                                           Comparable to TP10                                                     

  M918                                                               Higher than Penetratin                                \[[@B44-molecules-24-04318]\]                                          

  **α-helical amphipathic CPPs**                                     II                                                    High                                                                   \[[@B45-molecules-24-04318]\]
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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###### 

Top 70 CPPs' secondary structure prediction after conjugation with CPG2.

  Peptide Number   CPPs' Names                                   N-Terminal Conjugation with CPG2   C-Terminal Conjugation with CPG2                            
  ---------------- --------------------------------------------- ---------------------------------- ---------------------------------- ------------------------ ------
  **1**            Transportan 10 (TP10)                         CCSSSSSCHHHHCCCCCHHHC              57.1                               CCCCCCCCCCHHHHHHHHHCC    42.9
  **2**            Ala43 substitution mutant of pAntp (43--58)   CCHHHHHHHCCCCCHH                   56.2                               HHHHHHHHHHHHHHCC         87.5
  **3**            Crot (27--39) derivative 1                    CSSSSSHHHH                         90.0                               CCCSSSSCCC               40.0
  **4**            Crot (27--39) derivative 2                    CSSSSSSHHH                         90.0                               CCCSSSSCCC               40.0
  **5**            Crot (27--39) derivative 3                    CSSSSSSCHH                         80.0                               CCHHHSSCCC               50.0
  **6**            CyLoP-1                                       CSSSHHHHHH                         90.0                               CCCCCCCCCC               0.0
  **7**            Crot (27--39) derivative 4                    CCCCCCCCCCH                        9.1                                CCCCCCCCCCC              0.0
  **8**            Crot (27--39) derivative 5                    CCSSSSHHHHH                        81.8                               CHHHHHHCCCC              54.5
  **9**            pAntp (49--58)                                CCCCHHHHHH                         60.0                               CCCCCCCCCC               0.0
  **10**           Tat (48--60)                                  CCCCCCCCCCCCC                      0.0                                CCCCCCCCCCCCC            0.0
  **11**           pAntp (45--58)                                CCSSSCCCCCCCHH                     35.7                               CCCCCCCCCCCCCC           0.0
  **12**           Bip15                                         CCCCC                              0.0                                CCCCC                    0.0
  **13**           pAntp (47--58)                                CCCCCCCCCCHH                       16.7                               CCCCCCCCCCCC             0.0
  **14**           II                                            CHHHHHHHHHHHHHHHHH                 94.4                               HHHHHHHHHHHHHHHHCC       88.9
  **15**           Crot (27--39) derivative 6                    CCCCCCCCCC                         0.0                                CCCCCCCCCC               0.0
  **16**           Crot (27--39) derivative 7                    CCCCCCCCCCCCCH                     7.1                                CCHHHHHHHCCCCC           50.0
  **17**           Crot (27--39) derivative 8                    CCSSSSSCHHH                        27.3                               CCCCCCCCCCC              0.0
  **18**           Crot (27--39) derivative 9                    CCCSSSSHHHHH                       41.7                               CCCCCCCHHCCC             16.7
  **19**           pAntp (46--58)                                CCCCCCCCCCCHH                      15.4                               CCCCCHHHHHHCC            46.2
  **20**           7                                             CCCSSSCCCCCCCCH                    26.7                               CCCCCCCCCCCCCCC          0.0
  **21**           No.14--2                                      CHHHHHHHHHHHCCC                    73.3                               HHHCCCCHHHHCCCC          46.7
  **22**           No.14                                         CCSSSSSCCCCCCHH                    53.3                               CCCCCCCCCCCCCCC          0.0
  **23**           No.14--7                                      CCHHHHHCCCCHHHH                    60.0                               CCCCCCCCCCCCCCC          0.0
  **24**           Crot (27--39)                                 CCCSSSSSHHHHH                      76.9                               CCCCCHHHHHCCC            38.5
  **25**           Crot (27--39) derivative 10                   CCCCSSHHHHHH                       66.7                               CCCCCCCCCCCC             0.0
  **26**           Crot (27--39) derivative 11                   CCCCCCSSCCCHH                      30.8                               CCCCCCCCCCCCC            0.0
  **27**           Crot (27--39) derivative 12                   CCCSSSSHHHHHH                      76.9                               CCCCHHHHHHCCC            46.2
  **28**           pVEC mutant 1                                 CHHHHHHHHHCCCCCCCH                 55.5                               CCHHHHHHHHHHHHCCCC       66.7
  **29**           pVEC mutant 2                                 CCSSSHHHHHCCCCCCCC                 44.4                               HHHHHHHHHHHCCCCCCC       61.1
  **30**           pVEC mutant 3                                 CSSSHHHHHHHCCCCCCH                 61.1                               CCHHHHHHHHHHHCCCCC       61.1
  **31**           Crot (27--39) derivative 13                   CCCSSSSHHHHH                       75.0                               CCCCHHHHHCCC             41.7
  **32**           ARF(1--22)                                    CCCHHHHHHHHHHHHCCCCCCC             54.5                               HHHHHHHHHHHCCCCCCCCCCC   50.0
  **33**           M918                                          CCSSHHHHHHHHHHCCCCCCCC             54.5                               CCHHHHHHHHCCCCCCCCCCCC   36.4
  **34**           pAntp (51--58)                                CCCCCCHH                           25.0                               CCCCCCCC                 0.0
  **35**           pAntp (44--58)                                CCCHHHHCCCCCCHH                    40.0                               HHHHHHHHHCCCCCC          60.0
  **36**           pAntp (50--58)                                CCCCCCCHH                          22.2                               CCCCCCCCC                0.0
  **37**           Ala44 substitution mutant of pAntp (43--58)   CCCCHHHCCCCCCCHH                   31.2                               HHHHHHHHCCHHHCCC         68.8
  **38**           PDX -1-PTD                                    CCCHHHHCCCCCCCHH                   37.5                               HHHHHHHHHHHCCCCC         68.8
  **39**           No.14--25                                     CSSSSSCCCHHHHHH                    73.3                               CHHCCCCCCCCCCCC          13.3
  **40**           No.14--17                                     CSSSSCCCCCCHHHH                    53.3                               HHHHCCCCCCCCCCC          26.7
  **41**           No.14--18                                     CCSSSSSCCCCCCCC                    33.3                               HHHHHHHCCCCCCCC          46.7
  **42**           No.14--20                                     CCCCCCCCCCCCCCH                    6.7                                CCCCCCCCCCCCCCC          0.0
  **43**           No.14--21                                     CCSSSSSSCCCHHHH                    66.7                               HHHHHHHHHHHHHCC          86.7
  **44**           No.14--1135                                   CCSSSSSCCCCCCCC                    33.3                               CCCCCCCCCCCCCCC          0.0
  **45**           No.14--1                                      CCCSSSCCCCCCCHH                    33.3                               CCCCCCCCCCCCCCC          0.0
  **46**           30                                            CCCSSSCCCHHHHCC                    46.7                               CCCCCCCCCCCCCCC          0.0
  **47**           Ala45 substitution mutant of pAntp (43--58)   CCCSSSSCCCCCCCHH                   37.5                               HHHHHHHHHHHHHCCC         81.3
  **48**           Ala46 substitution mutant of pAntp (43--58)   CCSSSSSCCCCCCCHH                   43.7                               HHHHHHHCCCHHHHCC         68.8
  **49**           Ala47 substitution mutant of pAntp (43--58)   CCHHHCCCCCCCCCHH                   31.2                               HHHHHHHHHHCCCCCC         62.5
  **50**           Ala48 substitution mutant of pAntp (43--58)   CCHHHHHHHCCCCCCC                   43.7                               CCCCHHHCHHHHHCCC         50.0
  **51**           Ala49 substitution mutant of pAntp (43--58)   CCCSSCCCCCCCCCHH                   25                                 HHCCHHHHCCCHHCCC         50.0
  **52**           Ala50 substitution mutant of pAntp (43--58)   CCSSSSSCCCCCCCHH                   43.7                               HHHHHHHHHHHHCCCC         87.5
  **53**           pAntpHD (Pro50)                               CCCCCCCCCCCCCCHH                   12.5                               HHHHHHCCCCHHHCCC         68.8
  **54**           Ala51 substitution mutant of pAntp (43--58)   CCCSSSSCCCCCCCCH                   31.2                               CCCCCCHHHHHHHHCC         50.0
  **55**           Ala52 substitution mutant of pAntp(43--58)    CCHHHHHHHHHHHCCC                   68.7                               CCCCCHHHCCHHHCCC         37.5
  **56**           Met-Arg                                       CCHHHHHHHHHHHHHH                   87.5                               HHHHHHHHHHHHHHCC         87.5
  **57**           Ala54 substitution mutant of pAntp(43--58)    CSSSHHHCCCCCCCHH                   50.0                               HHHHHHHHCCHHHHCC         75.0
  **58**           Penetratin                                    CCSSSSSCCCCCCCCH                   37.5                               HHHHHHHHHHHHHHCC         87.5
  **59**           Retro - Tat (57--49)                          CCCCCCCCC                          0.0                                CCCCCCCCC                0.0
  **60**           R6                                            CCHHHH                             66.7                               CCCCCC                   0.0
  **61**           R9                                            CCCCCCCCC                          0.0                                CCCCHHCCC                22.2
  **62**           Crot (27--39) derivative 14                   CSSHHHHHH                          88.9                               CCCSSSCCC                33.3
  **63**           Crot (27--39) derivative 15                   CCSSSHHHHH                         80.0                               CCCCCCCCCC               0.0
  **64**           Rev (34--50)                                  CCCCCCCCCCCCCCCCC                  0.0                                CCCCCCCCCCCCCCCCC        0.0
  **65**           HIV-1 Rev (34--50)                            CCCCCCCCCHHHHHHHCCC                36.8                               CCCCCCCCCCCCCCCCCCC      0.0
  **66**           Bip6                                          CCCCC                              0.0                                CCCCC                    0.0
  **67**           Bip1                                          CCCCC                              0.0                                CCCCC                    0.0
  **68**           Bip2                                          CCCCC                              0.0                                CCCCC                    0.0
  **69**           Bip16                                         CCCCC                              0.0                                CCCCC                    0.0
  **70**           pAntp (48--58)                                CCCCCCCCCHH                        18.2                               CCCCCCCCCCC              0.0
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###### 

Physiochemical properties of CPP-CPG2 *N*-terminal conjugates.

  Peptide Number   Name of the Conjugate                              Number of Amino Acids   Mw (Da)    pI     Instability Index   Aliphatic Index   GRAVY
  ---------------- -------------------------------------------------- ----------------------- ---------- ------ ------------------- ----------------- --------
  **1**            Transportan 10 (TP10)-CPG2                         414                     43860.19   8.37   23.99               97.20             −0.116
  **2**            Ala43 substitution mutant of pAntp (43-58)-CPG2    409                     43839.07   8.82   25.71               91.69             −0.218
  **3**            Crot (27--39) derevative 1-CPG2                    403                     42996.11   8.48   24.58               90.87             −0.187
  **4**            Crot (27--39) derevative 2-CPG2                    403                     43035.15   8.48   26.37               90.87             −0.196
  **5**            Crot (27--39) derevative 3-CPG2                    403                     43035.15   8.48   26.00               90.87             −0.196
  **6**            CyLoP-1-CPG2                                       403                     43074.18   8.48   27.79               90.87             −0.205
  **7**            Crot (27--39) derevative 4-CPG2                    404                     43131.24   8.48   27.75               90.64             −0.206
  **8**            Crot (27--39) derevative 5-CPG2                    404                     43189.27   8.21   27.75               90.64             −0.214
  **9**            pAntp (49--58)-CPG2                                403                     43099.16   8.65   26.37               90.87             −0.228
  **10**           Tat (48--60)-CPG2                                  406                     43396.46   9.08   31.77               90.20             −0.279
  **11**           pAntp (45--58)-CPG2                                407                     43639.86   8.82   25.79               91.89             −0.215
  **12**           Bip15--CPG2                                        398                     42278.25   6.56   24.66               93.97             −0.159
  **13**           pAntp (47--58)-CPG2                                405                     43398.53   8.65   26.29               91.38             −0.218
  **14**           II-CPG2                                            411                     43554.90   8.64   23.83               97.20             −0.121
  **15**           Crot (27--39) derevative 6-CPG2                    403                     43074.18   8.48   26.37               90.87             −0.205
  **16**           Crot (27--39) derevative 7-CPG2                    407                     43419.60   8.61   27.62               89.98             −0.209
  **17**           Crot (27--39) derevative 8-CPG2                    404                     43202.36   8.66   27.75               90.64             −0.215
  **18**           Crot (27--39) derevative 9-CPG2                    405                     43317.45   8.47   27.70               90.42             −0.223
  **19**           pAntp (46--58)-CPG2                                406                     43526.70   8.82   26.04               91.16             −0.227
  **20**           7-CPG2                                             408                     43701.80   8.39   28.82               90.71             −0.215
  **21**           No.14--2-CPG2                                      408                     43652.73   8.38   27.74               90.96             −0.208
  **22**           No.14-CPG2                                         408                     43678.77   8.38   28.82               90.71             −0.216
  **23**           No.14--7-CPG2                                      408                     43763.88   8.38   28.38               90.71             −0.216
  **24**           Crot (27--39)-CPG2                                 406                     43448.64   8.47   28.46               90.20             −0.217
  **25**           Crot (27--39) derevative 10-CPG2                   405                     43345.50   8.53   28.51               90.42             −0.224
  **26**           Crot (27--39) derevative 11-CPG2                   406                     43432.58   8.53   28.46               90.20             −0.226
  **27**           Crot (27--39) derevative 12-CPG2                   406                     43432.58   8.53   29.27               90.20             −0.226
  **28**           pVEC mutant 1-CPG2                                 411                     43802.04   8.66   25.76               95.52             −0.169
  **29**           pVEC mutant 2-CPG2                                 411                     43802.04   8.66   27.15               95.52             −0.169
  **30**           pVEC mutant 3-CPG2                                 411                     43830.05   8.67   27.97               95.52             −0.171
  **31**           Crot (27--39) derevative 13-CPG2                   405                     43320.46   8.17   27.70               90.42             −0.208
  **32**           ARF(1--22)-CPG2                                    415                     44329.74   8.93   28.88               94.10             −0.158
  **33**           M918-CPG2                                          415                     44329.74   8.93   28.88               94.10             −0.158
  **34**           pAntp (51--58)-CPG2                                401                     42823.85   8.65   26.45               91.32             −0.227
  **35**           pAntp (44--58)-CPG2                                408                     43767.99   8.82   25.75               91.67             −0.223
  **36**           pAntp (50--58)-CPG2                                402                     42951.98   8.65   26.41               91.09             −0.235
  **37**           Ala44 substitution mutant of pAntp (43--58)-CPG2   409                     43867.13   8.95   25.71               91.69             −0.221
  **38**           PDX -1-PTD-CPG2                                    409                     43933.19   8.95   27.26               91.44             −0.233
  **39**           No.14--25-CPG2                                     408                     43628.71   8.39   27.26               90.71             −0.199
  **40**           No.14--17-CPG2                                     408                     43614.68   8.40   28.66               90.96             −0.210
  **41**           No.14--18-CPG2                                     408                     43690.78   8.39   29.00               90.96             −0.211
  **42**           No.14--20-CPG2                                     408                     43676.75   8.39   29.50               90.96             −0.211
  **43**           No.14--21-CPG2                                     408                     43676.75   8.39   29.02               90.96             −0.211
  **44**           No.14--35-CPG2                                     408                     43720.81   8.39   30.02               90.96             −0.212
  **45**           No.14--1-CPG2                                      408                     43706.78   8.39   29.02               90.71             −0.217
  **46**           30-CPG2                                            408                     43660.71   8.37   27.65               90.71             −0.219
  **47**           Ala45 substitution mutant of pAntp (43--58)-CPG2   409                     43882.10   8.95   26.39               90.73             −0.240
  **48**           Ala46 substitution mutant of pAntp (43--58)-CPG2   409                     43867.09   8.83   26.60               91.69             −0.220
  **49**           Ala47 substitution mutant of pAntp (43--58)-CPG2   409                     43882.10   8.95   26.39               90.73             −0.240
  **50**           Ala48 substitution mutant of pAntp (43--58)-CPG2   409                     43809.00   8.95   26.19               91.69             −0.227
  **51**           Ala49 substitution mutant of pAntp (43--58)-CPG2   409                     43848.08   8.95   25.82               91.69             −0.236
  **52**           Ala50 substitution mutant of pAntp (43--58)-CPG2   409                     43867.13   8.95   26.19               91.69             −0.221
  **53**           pAntpHD (Pro50)-CPG2                               409                     43893.17   8.95   26.66               91.44             −0.229
  **54**           Ala51 substitution mutant of pAntp (43--58)-CPG2   409                     43881.16   8.95   26.19               91.69             −0.221
  **55**           Ala52 substitution mutant of pAntp (43--58)-CPG2   409                     43839.07   8.82   24.78               91.69             −0.218
  **56**           Met-Arg-CPG2                                       409                     43924.18   8.95   26.00               91.44             −0.233
  **57**           Ala54 substitution mutant of pAntp (43--58)-CPG2   409                     43864.07   8.95   26.19               91.69             −0.234
  **58**           Penetratin-CPG2                                    409                     43924.18   8.95   26.19               91.44             −0.233
  **59**           Retro - Tat (57--49)-CPG2                          402                     43017.05   9.08   30.55               91.09             −0.264
  **60**           R6-CPG2                                            399                     42632.57   8.86   32.28               91.78             −0.238
  **61**           R9-CPG2                                            402                     43101.13   9.19   36.38               91.09             −0.269
  **62**           Crot (27--39) derevative 14-CPG2                   402                     42971.04   8.53   27.84               91.09             −0.212
  **63**           Crot (27--39) derevative 15-CPG2                   403                     43058.12   8.52   28.27               90.87             −0.214
  **64**           Rev (34--50)-CPG2                                  410                     44115.2    9.18   32.92               89.56             −0.309
  **65**           HIV-1 Rev (34--50)-CPG2                            412                     44275.39   9.13   32.60               89.13             −0.302
  **66**           Bip6-CPG2                                          398                     42204.11   6.55   25.89               93.97             −0.160
  **67**           Bip1-CPG2                                          398                     42264.22   6.55   25.22               93.72             −0.159
  **68**           Bip2-CPG2                                          398                     42234.13   6.55   25.41               93.72             −0.166
  **69**           Bip16-CPG2                                         398                     42234.09   6.22   26.44               93.72             −0.165
  **70**           pAntp (48--58)-CPG2                                404                     43285.37   8.65   26.33               90.64             −0.229
                   CPG2                                               393                     41695.44   6.22   25.33               93.18             −0.173
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###### 

Solubility prediction of CPG2 and top 70 CPPs conjugated to both *N*- and C-terminus of CPG2 using the ccsol server.

  Peptide Number   Name of the Conjugate                              The Solubility Percentage of CPP-CPG2 N-Terminal Conjugates   The Solubility Percentage of CPG2-CPP C-Terminal Conjugates
  ---------------- -------------------------------------------------- ------------------------------------------------------------- -------------------------------------------------------------
  **1**            Transportan 10 (TP10)-CPG2                         86%                                                           86%
  **2**            Ala43 substitution mutant of pAntp (43--58)-CPG2   79%                                                           79%
  **3**            Crot (27--39) derevative 1-CPG2                    87%                                                           84%
  **4**            Crot (27--39) derevative 2-CPG2                    86%                                                           83%
  **5**            Crot (27--39) derevative 3-CPG2                    86%                                                           83%
  **6**            CyLoP-1-CPG2                                       85%                                                           82%
  **7**            Crot (27--39) derevative 4-CPG2                    86%                                                           82%
  **8**            Crot (27--39) derevative 5-CPG2                    85%                                                           83%
  **9**            pAntp (49--58)-CPG2                                82%                                                           81%
  **10**           Tat (48--60)-CPG2                                  79%                                                           82%
  **11**           pAntp (45--58)-CPG2                                80%                                                           79%
  **12**           Bip15-CPG2                                         84%                                                           84%
  **13**           pAntp (47--58)-CPG2                                81%                                                           79%
  **14**           II-CPG2                                            87%                                                           88%
  **15**           Crot (27--39) derevative 6-CPG2                    81%                                                           85%
  **16**           Crot (27--39) derevative 7-CPG2                    84%                                                           85%
  **17**           Crot (27--39) derevative 8-CPG2                    85%                                                           83%
  **18**           Crot (27--39) derevative 9-CPG2                    84%                                                           84%
  **19**           pAntp (46--58)-CPG2                                81%                                                           80%
  **20**           7-CPG2                                             70%                                                           74%
  **21**           No.14--2-CPG2                                      70%                                                           74%
  **22**           No.14-CPG2                                         71%                                                           75%
  **23**           No.14--7-CPG2                                      70%                                                           74%
  **24**           Crot (27--39)-CPG2                                 84%                                                           83%
  **25**           Crot (27--39) derevative 10-CPG2                   83%                                                           83%
  **26**           Crot (27--39) derevative 11-CPG2                   83%                                                           83%
  **27**           Crot (27--39) derevative 12-CPG2                   83%                                                           82%
  **28**           pVEC mutant 1-CPG2                                 80%                                                           80%
  **29**           pVEC mutant 2-CPG2                                 80%                                                           80%
  **30**           pVEC mutant 3-CPG2                                 78%                                                           77%
  **31**           Crot (27--39) derevative 13-CPG2                   84%                                                           82%
  **32**           ARF(1--22)-CPG2                                    75%                                                           76%
  **33**           M918-CPG2                                          75%                                                           76%
  **34**           pAntp (51--58)-CPG2                                84%                                                           82%
  **35**           pAntp (44--58)-CPG2                                79%                                                           79%
  **36**           pAntp (50--58)-CPG2                                83%                                                           82%
  **37**           Ala44 substitution mutant of pAntp (43--58)-CPG2   79%                                                           78%
  **38**           PDX -1-PTD-CPG2                                    79%                                                           78%
  **39**           No.14--25-CPG2                                     73%                                                           75%
  **40**           No.14--17-CPG2                                     72%                                                           73%
  **41**           No.14--18-CPG2                                     71%                                                           72%
  **42**           No.14--20-CPG2                                     72%                                                           73%
  **43**           No.14--21-CPG2                                     72%                                                           73%
  **44**           No.14--35-CPG2                                     70%                                                           72%
  **45**           No.14--1-CPG2                                      71%                                                           72%
  **46**           30-CPG2                                            72%                                                           74%
  **47**           Ala45 substitution mutant of pAntp (43--58)-CPG2   79%                                                           78%
  **48**           Ala46 substitution mutant of pAntp (43--58)-CPG2   78%                                                           76%
  **49**           Ala47 substitution mutant of pAntp (43--58)-CPG2   80%                                                           78%
  **50**           Ala48 substitution mutant of pAntp (43--58)-CPG2   81%                                                           80%
  **51**           Ala49 substitution mutant of pAntp (43--58)-CPG2   80%                                                           78%
  **52**           Ala50 substitution mutant of pAntp (43--58)-CPG2   79%                                                           78%
  **53**           pAntpHD (Pro50)-CPG2                               79%                                                           78%
  **54**           Ala51 substitution mutant of pAntp (43--58)-CPG2   79%                                                           77%
  **55**           Ala52 substitution mutant of pAntp (43--58)-CPG2   80%                                                           79%
  **56**           Met-Arg-CPG2                                       79%                                                           78%
  **57**           Ala54 substitution mutant of pAntp (43--58)-CPG2   80%                                                           79%
  **58**           Penetratin-CPG2                                    79%                                                           78%
  **59**           Retro - Tat (57--49)-CPG2                          82%                                                           81%
  **60**           R6-CPG2                                            80%                                                           82%
  **61**           R9-CPG2                                            77%                                                           79%
  **62**           Crot (27--39) derevative 14-CPG2                   86%                                                           81%
  **63**           Crot (27--39) derevative 15-CPG2                   85%                                                           81%
  **64**           Rev (34--50)-CPG2                                  73%                                                           74%
  **65**           HIV-1 Rev (34--50)-CPG2                            74%                                                           73%
  **66**           Bip6-CPG2                                          84%                                                           85%
  **67**           Bip1-CPG2                                          84%                                                           85%
  **68**           Bip2-CPG2                                          84%                                                           85%
  **69**           Bip16-CPG2                                         83%                                                           85%
  **70**           pAntp (48--58)-CPG2                                82%                                                           79%
                   CPG2                                               83%                                                           83%
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###### 

Thermodynamic quantities of CPG2 and 70 top CPPs conjugated to CPG2 using the SCOOP server.

  Peptide Number   Name of the Conjugate                             *N-Terminal Conjugates*   *C-Terminal Conjugates*          
  ---------------- ------------------------------------------------- ------------------------- ------------------------- ------ -------
  **1**            Transportan 10 (TP10)-CPG2                        64.1                      −12.3                     60.9   −15.9
  **2**            Ala43 substitution mutant of pAntp (43-58)-CPG2   59.1                      −13.1                     60.7   −11.6
  **3**            Crot (27−39) derivative 1-CPG2                    61.2                      −13.3                     61.7   −13.1
  **4**            Crot (27−39) derivative 2-CPG2                    60.7                      −14.2                     61.7   −13.1
  **5**            Crot (27−39) derivative 3-CPG2                    61.3                      −14.1                     59.0   −14.0
  **6**            CyLoP-1-CPG2                                      62.0                      −13.2                     61.5   −13.6
  **7**            Crot (27−39) derivative 4-CPG2                    63.1                      −14.0                     65.8   −13.8
  **8**            Crot (27−39) derivative 5-CPG2                    62.4                      −13.1                     60.2   −15.0
  **9**            pAntp (49−58)-CPG2                                60.5                      −16.0                     59.3   −16.6
  **10**           Tat (48−60)-CPG2                                  60.1                      −13.4                     68.0   −13.6
  **11**           pAntp (45−58)-CPG2                                59.1                      −16.1                     60.0   −14.1
  **12**           Bip15-CPG2                                        60.7                      −12.7                     63.1   −14.4
  **13**           pAntp (47−58)-CPG2                                59.7                      −15.4                     62.2   −13.2
  **14**           II-CPG2                                           59.7                      −15.4                     62.5   −14.8
  **15**           Crot (27−39) derivative 6-CPG2                    62.8                      −13.3                     62.3   −12.9
  **16**           Crot (27−39) derivative 7-CPG2                    61.7                      −15.9                     64.1   −15.2
  **17**           Crot (27−39) derivative 8-CPG2                    61.1                      −14.8                     60.3   −15.9
  **18**           Crot (27−39) derivative 9-CPG2                    59.1                      −13.2                     61.7   −13.3
  **19**           pAntp (46−58)-CPG2                                63.0                      −12.7                     61.2   −14.6
  **20**           7-CPG2                                            62.7                      −12.8                     60.2   −12.8
  **21**           No.14−2-CPG2                                      61.9                      −15.1                     59.6   −13.6
  **22**           No.14-CPG2                                        64.7                      −15.4                     59.8   −14.8
  **23**           No.14−7-CPG2                                      63.6                      −14.4                     63.0   −12.6
  **24**           Crot (27−39)-CPG2                                 61.4                      −15.0                     61.0   −14.9
  **25**           Crot (27−39) derivative 10-CPG2                   60.6                      −14.7                     57.3   −13.0
  **26**           Crot (27−39) derivative 11-CPG2                   61.0                      −15.1                     58.9   −15.4
  **27**           Crot (27−39) derivative 12-CPG2                   60.5                      −13.6                     59.5   −13.9
  **28**           pVEC mutant 1-CPG2                                63.8                      −14.0                     64.2   −12.0
  **29**           pVEC mutant 2-CPG2                                60.2                      −16.8                     57.9   −15.8
  **30**           pVEC mutant 3-CPG2                                63.8                      −11.2                     62.1   −13.7
  **31**           Crot (27−39) derivative 13-CPG2                   64.2                      −14.3                     58.5   −13.3
  **32**           ARF(1−22)-CPG2                                    61.0                      −16.3                     65.4   −12.4
  **33**           M918-CPG2                                         65.5                      −14.8                     63.3   −12.6
  **34**           pAntp (51−58)-CPG2                                56.9                      −15.8                     61.6   −15.3
  **35**           pAntp (44−58)-CPG2                                58.1                      −13.6                     59.5   −16.8
  **36**           pAntp (50−58)-CPG2                                62.7                      −15.6                     61.0   −13.6
  **37**           Ala44 substitution mutant of pAntp (43−58)-CPG2   60.7                      −13.8                     58.4   −15.6
  **38**           PDX -1-PTD-CPG2                                   57.6                      −13.9                     58.5   −14.2
  **39**           No.14−25-CPG2                                     62.3                      −11.5                     58.5   −15.3
  **40**           No.14−17-CPG2                                     60.3                      −14.6                     58.7   −14.9
  **41**           No.14−18-CPG2                                     60.6                      −13.3                     61.6   −13.9
  **42**           No.14−20-CPG2                                     62.3                      −14.1                     56.6   −15.2
  **43**           No.14−21-CPG2                                     63.8                      −14.8                     60.8   −14.2
  **44**           No.14−35-CPG2                                     62.5                      −15.9                     59.9   −15.4
  **45**           No.14−1-CPG2                                      61.7                      −15.5                     60.7   −13.4
  **46**           30-CPG2                                           62.8                      −13.8                     58.3   −15.0
  **47**           Ala45 substitution mutant of pAntp (43−58)-CPG2   60.2                      −14.0                     59.7   −16.3
  **48**           Ala46 substitution mutant of pAntp (43−58)-CPG2   63.2                      −12.9                     60.4   −14.6
  **49**           Ala47 substitution mutant of pAntp (43−58)-CPG2   60.6                      −13.6                     61.3   −13.0
  **50**           Ala48 substitution mutant of pAntp (43−58)-CPG2   62.2                      −14.0                     57.1   −16.1
  **51**           Ala49 substitution mutant of pAntp (43−58)-CPG2   61.1                      −14.6                     60.7   −14.7
  **52**           Ala50 substitution mutant of pAntp (43−58)-CPG2   60.8                      −13.3                     59.5   −15.3
  **53**           pAntpHD (Pro50)-CPG2                              62.7                      −12.7                     60.7   −13.4
  **54**           Ala51 substitution mutant of pAntp (43−58)-CPG    60.3                      −14.9                     56.6   −13.4
  **55**           Ala52 substitution mutant of pAntp (43−58)-CPG2   63.9                      −11.9                     61.1   −13.4
  **56**           Met-Arg-CPG2                                      64.2                      −14.3                     59.6   −14.3
  **57**           Ala54 substitution mutant of pAntp (43−58)-CPG2   60.4                      −14.7                     59.5   −14.9
  **58**           Penetratin-CPG2                                   60.4                      −15.1                     60.0   −12.5
  **59**           Retro - Tat (57−49)-CPG2                          61.0                      −14.0                     60.4   −14.7
  **60**           R6-CPG2                                           58.7                      −14.3                     62.0   −14.4
  **61**           R9-CPG2                                           62.7                      −13.8                     57.7   −15.5
  **62**           Crot (27−39) derivative 14-CPG2                   63.5                      −13.2                     62.6   −13.0
  **63**           Crot (27−39) derivative 15-CPG2                   60.3                      −13.6                     63.0   −15.1
  **64**           Rev (34−50)-CPG2                                  59.1                      −16.4                     58.5   −16.0
  **65**           HIV-1 Rev (34−50)-CPG2                            62.0                      −13.3                     59.9   −15.2
  **66**           Bip6-CPG2                                         62.6                      −15.0                     62.6   −13.9
  **67**           Bip1-CPG2                                         56.7                      −14.9                     63.4   −11.2
  **68**           Bip2-CPG2                                         60.8                      −13.7                     60.5   −13.0
  **69**           Bip16-CPG2                                        61.8                      −14.6                     61.4   −14.3
  **70**           pAntp (48−58)-CPG2                                56.5                      −15.6                     59.5   −13.5
                   CPG2                                              61.7                      −15.1                     61.7   −15.1
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###### 

Result of the stability analyses of CPG2 and top 70 CPPs conjugated to CPG2 using the FoldX suite server.

  Peptide Number   Name of the Conjugate                              *N-Terminal Conjugates*   *C-Terminal Conjugates*             
  ---------------- -------------------------------------------------- ------------------------- ------------------------- --------- --------
  **1**            Transportan 10 (TP10)-CPG2                         −129.40                   225.54                    −109.75   280.94
  **2**            Ala43 substitution mutant of pAntp (43-58)-CPG2    −122.58                   276.34                    −116.80   290.77
  **3**            Crot (27--39) derivative 1-CPG2                    −124.28                   212.60                    −116.83   231.74
  **4**            Crot (27--39) derivative 2-CPG2                    −118.09                   244.42                    −116.83   231.74
  **5**            Crot (27--39) derivative 3-CPG2                    −124.84                   201.96                    −116.51   221.44
  **6**            CyLoP-1-CPG2                                       −114.78                   222.25                    −121.71   237.72
  **7**            Crot (27--39) derivative 4-CPG2                    −118.05                   240.24                    −117.87   258.05
  **8**            Crot (27--39) derivative 5-CPG2                    −111.72                   242.79                    −122.19   226.79
  **9**            pAntp (49--58)-CPG2                                −117.91                   213.28                    −128.23   192.93
  **10**           Tat (48--60)-CPG2                                  −113.01                   237.15                    −110.09   285.79
  **11**           pAntp (45--58)-CPG2                                −109.21                   257.80                    −123.56   222.57
  **12**           Bip15-CPG2                                         −111.99                   219.08                    −110.39   206.12
  **13**           pAntp (47--58)-CPG2                                −115.32                   251.89                    −119.12   257.36
  **14**           II-CPG2                                            −118.36                   220.02                    −120.90   269.15
  **15**           Crot (27--39) derivative 6-CPG2                    −122.01                   240.34                    −112.90   247.76
  **16**           Crot (27--39) derivative 7-CPG2                    −114.80                   218.64                    −104.19   264.74
  **17**           Crot (27--39) derivative 8-CPG2                    −113.66                   231.91                    −118.05   228.78
  **18**           Crot (27--39) derivative 9-CPG2                    −129.44                   213.50                    −116.83   261.88
  **19**           pAntp (46--58)-CPG2                                −129.66                   234.61                    −122.16   220.00
  **20**           7-CPG2                                             −118.37                   248.66                    −113.78   227.61
  **21**           No.14--2-CPG2                                      −128.25                   266.61                    −106.97   305.73
  **22**           No.14-CPG2                                         −121.58                   288.14                    −125.08   244.91
  **23**           No.14--7-CPG2                                      −106.30                   268.12                    −120.60   253.67
  **24**           Crot (27--39)-CPG2                                 −121.32                   239.73                    −121.87   211.89
  **25**           Crot (27--39) derivative 10-CPG2                   −123.15                   236.04                    −119.18   232.36
  **26**           Crot (27--39) derivative 11-CPG2                   −117.73                   240.33                    −120.16   223.44
  **27**           Crot (27--39) derivative 12-CPG2                   −119.24                   236.96                    −125.03   239.37
  **28**           pVEC mutant 1-CPG2                                 −122.35                   279.77                    −112.86   279.81
  **29**           pVEC mutant 2-CPG2                                 −118.54                   275.22                    −114.38   236.84
  **30**           pVEC mutant 3-CPG2                                 −123.99                   238.03                    −118.77   231.76
  **31**           Crot (27--39) derivative 13-CPG2                   −117.23                   274.19                    −124.87   208.41
  **32**           ARF(1--22)-CPG2                                    −116.67                   287.55                    −127.44   277.30
  **33**           M918-CPG2                                          −100.79                   353.34                    −120.74   304.20
  **34**           pAntp (51--58)-CPG2                                −120.11                   213.01                    −119.48   227.21
  **35**           pAntp (44--58)-CPG2                                −120.79                   271.81                    −113.18   237.39
  **36**           pAntp (50--58)-CPG2                                −117.81                   219.53                    −116.73   245.44
  **37**           Ala44 substitution mutant of pAntp (43-58)-CPG2    −131.75                   260.06                    −107.05   248.14
  **38**           PDX -1-PTD-CPG2                                    −118.12                   230.27                    −123.45   254.56
  **39**           No.14--25-CPG2                                     −117.33                   259.77                    −111.95   223.28
  **40**           No.14--17-CPG2                                     −122.74                   201.85                    −124.49   287.89
  **41**           No.14--18-CPG2                                     −110.20                   279.65                    −111.53   235.99
  **42**           No.14--20-CPG2                                     −113.46                   286.37                    −120.35   235.61
  **43**           No.14--21-CPG2                                     −123.65                   306.20                    −103.28   271.59
  **44**           No.14--35-CPG2                                     −118.98                   316.52                    −127.82   288.57
  **45**           No.14--1-CPG2                                      −117.56                   288.64                    −111.92   232.73
  **46**           30-CPG2                                            −114.00                   274.45                    −112.39   225.22
  **47**           Ala45 substitution mutant of pAntp (43--58)-CPG2   −121.63                   244.81                    −128.84   256.18
  **48**           Ala46 substitution mutant of pAntp (43--58)-CPG2   −114.00                   258.27                    −109.97   275.43
  **49**           Ala47 substitution mutant of pAntp (43--58)-CPG2   −111.21                   279.55                    −118.80   250.65
  **50**           Ala48 substitution mutant of pAntp (43--58)-CPG2   −115.90                   215.33                    −113.15   225.09
  **51**           Ala49 substitution mutant of pAntp (43--58)-CPG2   −120.58                   259.79                    −125.14   244.61
  **52**           Ala50 substitution mutant of pAntp (43--58)-CPG2   −122.21                   266.42                    −117.50   275.80
  **53**           pAntpHD (Pro50)-CPG2                               −116.73                   247.08                    −113.98   279.80
  **54**           Ala51 substitution mutant of pAntp (43--58)-CPG2   −120.61                   256.74                    −117.29   277.38
  **55**           Ala52 substitution mutant of pAntp (43--58)-CPG2   −114.28                   273.55                    −127.58   224.55
  **56**           Met-Arg-CPG2                                       −120.88                   294.89                    −130.43   225.80
  **57**           Ala54 substitution mutant of pAntp (43--58)-CPG2   −113.18                   274.17                    −126.16   223.46
  **58**           Penetratin-CPG2                                    −114.09                   237.56                    −114.95   232.56
  **59**           Retro - Tat (57--49)-CPG2                          −104.71                   239.28                    −115.58   209.58
  **60**           R6-CPG2                                            −108.43                   215.13                    −120.23   219.49
  **61**           R9-CPG2                                            −126.43                   207.16                    −138.39   218.37
  **62**           Crot (27--39) derivative 14-CPG2                   −116.15                   187.59                    −117.38   233.60
  **63**           Crot (27--39) derivative 15-CPG2                   −109.48                   259.98                    −112.67   226.84
  **64**           Rev (34--50)-CPG2                                  −140.73                   250.30                    −120.99   267.37
  **65**           HIV-1 Rev (34--50)-CPG2                            −123.81                   241.35                    −120.42   237.54
  **66**           Bip6-CPG2                                          −126.11                   176.25                    −117.74   237.91
  **67**           Bip1-CPG2                                          −120.74                   163.93                    −125.52   199.54
  **68**           Bip2-CPG2                                          −106.63                   227.56                    −122.97   213.03
  **69**           Bip16-CPG2                                         −118.69                   199.30                    −126.85   187.15
  **70**           pAntp (48--58)-CPG2                                −121.70                   239.55                    −125.92   230.92
                   CPG2                                               −124.91                   203.85                    −124.91   203.85

molecules-24-04318-t008_Table 8

###### 

Result of folding rate prediction using the Foldrate server and backbone flexibility analysis by the Dynamine server for CPG2 and 70 top CPPs conjugated to CPG2.

  Peptide Number   Name of the Conjugate                              *N-Terminal Conjugates*   *C-Terminal Conjugates*
  ---------------- -------------------------------------------------- ------------------------- -------------------------
  **1**            Transportan 10 (TP10)-CPG2                         315.75                    292.07
  **2**            Ala43 substitution mutant of pAntp (43-58)-CPG2    341.86                    375.47
  **3**            Crot (27--39) derivative 1-CPG2                    269.35                    294.03
  **4**            Crot (27--39) derivative 2-CPG2                    266.25                    297.08
  **5**            Crot (27--39) derivative 3-CPG2                    266.25                    297.08
  **6**            CyLoP-1-CPG2                                       263.17                    296.95
  **7**            Crot (27--39) derivative 4-CPG2                    290.06                    299.60
  **8**            Crot (27--39) derivative 5-CPG2                    251.58                    269.07
  **9**            pAntp (49--58)-CPG2                                260.00                    265.84
  **10**           Tat (48--60)-CPG2                                  250.01                    261.29
  **11**           pAntp (45--58)-CPG2                                326.14                    336.71
  **12**           Bip15-CPG2                                         254.99                    251.17
  **13**           pAntp (47--58)-CPG2                                312.02                    325.60
  **14**           II-CPG2                                            282.10                    260.72
  **15**           Crot (27--39) derivative 6-CPG2                    272.11                    300.16
  **16**           Crot (27--39) derivative 7-CPG2                    300.50                    310.30
  **17**           Crot (27--39) derivative 8-CPG2                    262.57                    286.80
  **18**           Crot (27--39) derivative 9-CPG2                    251.02                    271.45
  **19**           pAntp (46--58)-CPG2                                314.64                    324.84
  **20**           7-CPG2                                             304.54                    328.42
  **21**           No.14--2-CPG2                                      303.00                    306.34
  **22**           No.14-CPG2                                         312.62                    340.53
  **23**           No.14--7-CPG2                                      288.59                    325.49
  **24**           Crot (27--39)-CPG2                                 262.67                    283.81
  **25**           Crot (27--39) derivative 10-CPG2                   263.85                    297.45
  **26**           Crot (27--39) derivative 11-CPG2                   287.51                    303.33
  **27**           Crot (27--39) derivative 12-CPG2                   281.35                    296.93
  **28**           pVEC mutant 1-CPG2                                 318.66                    318.66
  **29**           pVEC mutant 2-CPG2                                 308.37                    318.66
  **30**           pVEC mutant 3-CPG2                                 331.94                    310.97
  **31**           Crot (27--39) derivative 13-CPG2                   257.41                    310.97
  **32**           ARF(1--22)-CPG2                                    375.57                    426.04
  **33**           M918-CPG2                                          371.56                    371.56
  **34**           pAntp (51--58)-CPG2                                246.89                    371.56
  **35**           pAntp (44--58)-CPG2                                341.31                    359.69
  **36**           pAntp (50--58)-CPG2                                253.19                    371.56
  **37**           Ala44 substitution mutant of pAntp (43--58)-CPG2   339.30                    371.56
  **38**           PDX -1-PTD-CPG2                                    354.49                    371.56
  **39**           No.14--25-CPG2                                     302.06                    325.92
  **40**           No.14--17-CPG2                                     286.95                    325.92
  **41**           No.14--18-CPG2                                     316.39                    325.92
  **42**           No.14--20-CPG2                                     300.29                    325.92
  **43**           No.14--21-CPG2                                     303.60                    341.55
  **44**           No.14--35-CPG2                                     309.58                    341.55
  **45**           No.14--1-CPG2                                      315.26                    341.55
  **46**           30-CPG2                                            311.23                    328.53
  **47**           Ala45 substitution mutant of pAntp (43--58)-CPG2   321.46                    368.26
  **48**           Ala46 substitution mutant of pAntp (43--58)-CPG2   341.11                    368.26
  **49**           Ala47 substitution mutant of pAntp (43--58)-CPG2   301.29                    364.51
  **50**           Ala48 substitution mutant of pAntp (43--58)-CPG2   301.06                    364.51
  **51**           Ala49 substitution mutant of pAntp (43--58)-CPG2   328.09                    338.69
  **52**           Ala50 substitution mutant of pAntp (43--58)-CPG2   342.91                    357.57
  **53**           pAntpHD (Pro50)-CPG2                               324.61                    342.27
  **54**           Ala51 substitution mutant of pAntp (43--58)-CPG2   342.47                    342.27
  **55**           Ala52 substitution mutant of pAntp (43--58)-CPG2   300.29                    364.03
  **56**           Met-Arg-CPG2                                       298.31                    315.14
  **57**           Ala54 substitution mutant of pAntp (43--58)-CPG2   295.42                    305.35
  **58**           Penetratin-CPG2                                    354.39                    400.84
  **59**           Retro - Tat (57--49)-CPG2                          243.94                    246.69
  **60**           R6-CPG2                                            255.43                    249.84
  **61**           R9-CPG2                                            269.07                    249.03
  **62**           Crot (27--39) derivative 14-CPG2                   258.50                    276.26
  **63**           Crot (27--39) derivative 15-CPG2                   255.15                    263.85
  **64**           Rev (34--50)-CPG2                                  265.86                    251.26
  **65**           HIV-1 Rev (34--50)-CPG2                            276.22                    261.16
  **66**           Bip6-CPG2                                          239.77                    256.43
  **67**           Bip1-CPG2                                          256.15                    259.01
  **68**           Bip2-CPG2                                          240.98                    260.66
  **69**           Bip16-CPG2                                         242.18                    262.04
  **70**           pAntp (48--58)-CPG2                                300.95                    278.92
                   CPG2                                               229.89                    229.89
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###### 

Analysis of top 70 CPPs and top 70 CPPs conjugated to CPG2 for in vivo application.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Peptide Number   CPPs' Name                                    Immunogenicity of Respective CPP-CPG2 /CPG2-CPP Conjugate   Toxicity of CPPs   Hemolysis Potency of CPPs\   
                                                                                                                                                (PROB Score)                 
  ---------------- --------------------------------------------- ----------------------------------------------------------- ------------------ ---------------------------- ------
  **1**            Transportan 10 (TP10)                         0.6620                                                      0.6790             non-toxin                    0.83

  **2**            Ala43 substitution mutant of pAntp (43--58)   0.6874                                                      0.6907             non-toxin                    0.48

  **3**            Crot (27--39) derivative 1                    0.7201                                                      0.7267             Toxin                        0.49

  **4**            Crot (27--39) derivative 2                    0.7199                                                      0.7263             Toxin                        0.49

  **5**            Crot (27--39) derivative 3                    0.7238                                                      0.7319             Toxin                        0.49

  **6**            CyLoP-1                                       0.7244                                                      0.7323             Toxin                        0.49

  **7**            Crot (27--39) derivative 4                    0.7361                                                      0.7403             non-toxin                    0.49

  **8**            Crot (27--39) derivative 5                    0.7276                                                      0.7334             Toxin                        0.49

  **9**            pAntp (49--58)                                0.6973                                                      0.7017             non-toxin                    0.48

  **10**           Tat (48--60)                                  0.7208                                                      0.7385             non-toxin                    0.49

  **11**           pAntp (45--58)                                0.6910                                                      0.6794             non-toxin                    0.49

  **12**           Bip15                                         0.6929                                                      0.6903             non-toxin                    0.49

  **13**           pAntp (47--58)                                0.6855                                                      0.6690             non-toxin                    0.48

  **14**           II                                            0.6466                                                      0.6521             non-toxin                    0.83

  **15**           Crot (27--39) derivative 6                    0.7219                                                      0.7300             Toxin                        0.49

  **16**           Crot (27--39) derivative 7                    0.7439                                                      0.7410             non-toxin                    0.49

  **17**           Crot (27--39) derivative 8                    0.7267                                                      0.7314             Toxin                        0.49

  **18**           Crot (27--39) derivative 9                    0.7263                                                      0.7363             Toxin                        0.49

  **19**           pAntp (46--58)                                0.6813                                                      0.6764             non-toxin                    0.49

  **20**           7                                             0.6942                                                      0.6961             non-toxin                    0.49

  **21**           No.14--2                                      0.6961                                                      0.6980             non-toxin                    0.49

  **22**           No.14                                         0.6915                                                      0.6934             non-toxin                    0.49

  **23**           No.14--7                                      0.6844                                                      0.6863             non-toxin                    0.49

  **24**           Crot (27--39)                                 0.7371                                                      0.7409             Toxin                        0.49

  **25**           Crot (27--39) derivative 10                   0.7366                                                      0.7388             Toxin                        0.49

  **26**           Crot (27--39) derivative 11                   0.7344                                                      0.7406             Toxin                        0.49

  **27**           Crot (27--39) derivative 12                   0.7307                                                      0.7327             non-toxin                    0.49

  **28**           pVEC mutant 1                                 0.7006                                                      0.6886             non-toxin                    0.32

  **29**           pVEC mutant 2                                 0.6874                                                      0.6755             non-toxin                    0.32

  **30**           pVEC mutant 3                                 0.6901                                                      0.6782             non-toxin                    0.31

  **31**           Crot (27--39) derivative 13                   0.7304                                                      0.7344             Toxin                        0.49

  **32**           ARF(1--22)                                    0.6848                                                      0.6917             non-toxin                    0.48

  **33**           M918                                          0.6865                                                      0.6893             non-toxin                    0.48

  **34**           pAntp (51--58)                                0.7023                                                      0.7142             non-toxin                    0.49

  **35**           pAntp (44--58)                                0.6892                                                      0.6913             non-toxin                    0.49

  **36**           pAntp (50--58)                                0.7037                                                      0.7153             non-toxin                    0.49

  **37**           Ala44 substitution mutant of pAntp (43--58)   0.6840                                                      0.6866             non-toxin                    0.48

  **38**           PDX -1-PTD                                    0.6845                                                      0.6861             non-toxin                    0.49

  **39**           No.14--25                                     0.6910                                                      0.6907             non-toxin                    0.49

  **40**           No.14--17                                     0.6889                                                      0.6900             non-toxin                    0.49

  **41**           No.14--18                                     0.6927                                                      0.6938             non-toxin                    0.49

  **42**           No.14--20                                     0.6922                                                      0.6933             non-toxin                    0.48

  **43**           No.14--21                                     0.6949                                                      0.6961             non-toxin                    0.48

  **44**           No.14--35                                     0.6924                                                      0.6938             non-toxin                    0.49

  **45**           No.14--1                                      0.6929                                                      0.6941             non-toxin                    0.49

  **46**           30                                            0.6981                                                      0.7012             non-toxin                    0.49

  **47**           Ala45 substitution mutant of pAntp (43--58)   0.6741                                                      0.6817             non-toxin                    0.47

  **48**           Ala46 substitution mutant of pAntp (43--58)   0.6756                                                      0.6765             non-toxin                    0.47

  **49**           Ala47 substitution mutant of pAntp (43--58)   0.6740                                                      0.6779             non-toxin                    0.47

  **50**           Ala48 substitution mutant of pAntp (43--58)   0.7007                                                      0.7046             non-toxin                    0.48

  **51**           Ala49 substitution mutant of pAntp (43--58)   0.6784                                                      0.6823             non-toxin                    0.48

  **52**           Ala50 substitution mutant of pAntp (43--58)   0.6827                                                      0.6865             non-toxin                    0.48

  **53**           pAntpHD (Pro50)                               0.6887                                                      0.6926             non-toxin                    0.49

  **54**           Ala51 substitution mutant of pAntp (43--58)   0.6878                                                      0.6916             non-toxin                    0.48

  **55**           Ala52 substitution mutant of pAntp (43--58)   0.6932                                                      0.6970             non-toxin                    0.48

  **56**           Met-Arg                                       0.6792                                                      0.6833             non-toxin                    0.48

  **57**           Ala54 substitution mutant of pAntp (43--58)   0.6791                                                      0.6828             non-toxin                    0.48

  **58**           Penetratin                                    0.6820                                                      0.6859             non-toxin                    0.48

  **59**           Retro - Tat (57--49)                          0.7094                                                      0.7274             non-toxin                    0.17

  **60**           R6                                            0.6983                                                      0.7184             non-toxin                    0.49

  **61**           R9                                            0.7084                                                      0.7284             non-toxin                    0.49

  **62**           Crot (27--39) derivative 14                   0.7263                                                      0.7208             Toxin                        0.49

  **63**           Crot (27--39) derivative 15                   0.7182                                                      0.7284             Toxin                        0.49

  **64**           Rev (34--50)                                  0.7032                                                      0.7193             non-toxin                    0.49

  **65**           HIV-1 Rev (34--50)                            0.7128                                                      0.7213             non-toxin                    0.48

  **66**           Bip6                                          0.6956                                                      0.6980             non-toxin                    0.49

  **67**           Bip1                                          0.6920                                                      0.6924             non-toxin                    0.49

  **68**           Bip2                                          0.6945                                                      0.6984             non-toxin                    0.49

  **69**           Bip16                                         0.6957                                                      0.6968             non-toxin                    0.49

  **70**           pAntp (48--58)                                0.6838                                                      0.6695             non-toxin                    0.47

                   CPG2                                          0.7012                                                      0.7012             \-                           \-
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
